# Systematic Review of the Literature

The Effectiveness of Injection of Steroid with or without Local Anaesthetic to the Plantar Fascia

### **Prepared for:**

Amanda Bowens,
Information Specialist
The Accident Compensation Corporation
PO Box 242
Wellington 6011
New Zealand

### **Prepared by:**

International Centre for Allied Health Evidence
University of South Australia
Adelaide
SA 5000
Australia



University of South Australia

International Centre for Allied Health Evidence &CAHE

A member of the Sansom Institute



#### RESEARCH CENTRE RESPONSIBLE FOR THE PROJECT

#### **International Centre for Allied Health Evidence**

School of Health Sciences City East Campus University of South Australia Adelaide South Australia 5000

Website: www.unisa.edu.au/cahe

#### **Review team**

Heath Pillen Steve Milanese Karen Grimmer Ashley Fulton Holly Bowen Emile Sach

#### **Centre Director**

Professor Karen Grimmer Phone: (08) 8302 2769 Fax: (08) 8302 2766

Email: karen.grimmer@unisa.edu.au

#### **Project administrator**

Ms. Madeleine Mallee Business Services Officer Business Development Unit Division of Health Sciences University of South Australia Phone: (08) 8302 2121

Email: madeleine.mallee@unisa.edu.au

#### **Citation details**

Fax: (08) 8302 1472

The International Centre for Allied Health Evidence (2017) Systematic Review of the Literature: The Effectiveness of Injection of Steroid with or without Local Anaesthetic to the Plantar Fascia: Technical Report. Prepared for the Accident Compensation Corporation, New Zealand.





# **Table of Contents**

#### **Contents**

| Executive Summary   | 5  |
|---|----|
| 1. Background   | 7  |
| 1.1 Objective of this review  | 7  |
| 1.2 Description of the Intervention   | 7  |
| 1.3 Safety/Risk   | 8  |
| 2. Methodology  | 10 |
| 2.1 Review question   | 10 |
| 2.2 Methods   | 10 |
| 2.3 Search strategy   | 10 |
| 2.4 Study Selection   | 11 |
| 2.5 Critical Appraisal  | 12 |
| 2.6 Data Extraction   | 12 |
| 2.7 Data Synthesis  | 12 |
| 2.8 Grade of Recommendation   | 14 |
| 3. Results  | 15 |
| 3.1 Evidence Sources  | 16 |
| 3.2 Quality of the Evidence   | 16 |
| 3.3 Findings  | 17 |
| 3.4 Outcome Measures – Pain and Function  | 17 |
| 3.5 Outcome Measures – Safety and Risk  | 28 |
| 3.6 Economic analysis   | 29 |
| 4. Recommendations  | 30 |
| 5. References   |    |
| 6. Appendices   | 36 |
| Appendix 1 – Search string used in this review                                      | 36 |
| Appendix 2 – SIGN checklists used in this review                                    | 37 |
| Appendix 3 – Quality scores for articles used in this review (systematic reviews)   | 43 |
| Appendix 4 – RCTs included in SRs   | 44 |
| Appendix 5 – Quality scores for articles used in this review (RCTs)                 | 45 |
| Appendix 6 – Quality scores for articles used in this review (case-control studies) | 47 |
| Appendix 7 – Data extraction table used in this review (systematic reviews)         | 48 |
| Appendix 8 – Data extraction table used in this review (RCTs)                       | 50 |





# **Abbreviations**

The following abbreviations are used in this report and are listed here for convenience.

| Abbreviat  | Abbreviation                                    |  |  |  |  |
|------------|---|--|--|--|--|
| ABI        | Autologous blood injection                      |  |  |  |  |
| BTX-A      | Botulinum toxin type A                          |  |  |  |  |
| PF         | Plantar fasciitis                               |  |  |  |  |
| ССТ        | Controlled clinical trial                       |  |  |  |  |
| CSI        | Corticosteroid injection                        |  |  |  |  |
| c-hAM      | Cryopreserved human amniotic membrane           |  |  |  |  |
| ESWT       | Extracorporeal shock wave therapy               |  |  |  |  |
| iCAHE      | International Centre for Allied Health Evidence |  |  |  |  |
| NSAIDs     | Non-Steroidal Anti-Inflammatory Drugs           |  |  |  |  |
| PF         | Plantar fasciitis                               |  |  |  |  |
| PRP        | Platelet-rich plasma                            |  |  |  |  |
| RCT        | Randomised controlled trial                     |  |  |  |  |
| SIGN       | Scottish Intercollegiate Guidelines Network     |  |  |  |  |
| SR         | Systematic review                               |  |  |  |  |
| US         | Ultrasound                                      |  |  |  |  |
| Quality Ra | itings  |  |  |  |  |
| AQ         | Acceptable Quality                              |  |  |  |  |
| CS         | Can't say                                       |  |  |  |  |
| HQ         | High Quality                                    |  |  |  |  |
| QS         | Quality of Study                                |  |  |  |  |
| LQ         | Low Quality                                     |  |  |  |  |
| NA         | Not Applicable                                  |  |  |  |  |
| R          | Reject (Unacceptable Quality)                   |  |  |  |  |





# **Executive Summary**

# Objective of the Review

The objective of this review is to synthesise the evidence related to the effectiveness of injection of steroid to the plantar fascia as a form of interventional pain management for plantar fasciitis/fasciopathy. This review aims to answer the following research questions:

- a) What is the evidence for the effectiveness of steroid injections to the plantar fascia in relieving plantar heel pain?
- b) What is the evidence for the effectiveness of steroid injections to the plantar fascia in improving functional outcomes in patients?
- c) What is the evidence for the safety of steroid injections to the plantar fascia?

#### **Evidence sourced**

The search yielded 657 articles. After scrutiny, 582 articles were excluded as duplicates or failing to meet the inclusion criteria, leaving 75 studies for inclusion in this review including 11 systematic reviews, 34 randomised controlled trials, eight controlled clinical trials, one case-control study, and 23 case study or case series reports.

#### **Evidence of Effectiveness against Placebo**

• Steroid injection to the plantar fascia appear to be effective at reducing pain in the short-term (<3months post-treatment) when compared to placebo, but fails to offer any significant benefit in the long-term (Grade of Recommendation: A, based on one HQ SR, one HQ RCTs, one AQ SR, and two LQ SRs)

#### **Evidence of Effectiveness compared with Conservative (non-invasive) Treatments**

- Steroid injection to the plantar fascia is likely to be more effective at reducing pain in the short-term (<3months post-treatment) compared with physical therapies; however, has comparable effectiveness in the long-term (Grade of Recommendation: B, based on one HQ SR and one HQ RCT)
- Steroid injection is more effective than use of silicone insoles at reducing pain in the short-term (<3 months post-treatment), with inconsistent results for relative long-term effectiveness (Grade of Recommendation B: based on one HQ RCT)
- Steroid injection comparable to extracorporeal shockwave therapy in reducing pain in the long-term (≥3 months post-treatment), with inconsistent results regarding short-term effectiveness (Grade of Recommendation: B, based on one HQ SR, one HQ RCT, and one AQ RCT)

#### Evidence of Effectiveness compared with Alternative (invasive) Treatments

- Steroid injection is superior to autologous blood injection at reducing pain in the shortterm (<3months post-treatment); however, has comparable effectiveness in the longterm (Grade of Recommendation: B, based on two HQ SRs, one LQ SR, and one LQ RCTs)
- Steroid injection is inferior to injection with botulinum toxin type A at reducing pain in the short and long-term (Grade of Recommendation B: based on one HQ RCT)
- Steroid injection is inferior to miniscalpel-needle release treatment at reducing pain in the short and long-term (Grade of Recommendation B: based on one HQ RCT)

evidence for the effectiveness of steroid injections to the plantar fascia in relieving pain and/or in improving functional outcomes in patients with plantar fasciitis or fasciopathy?

What is the





|  | Insufficient Body of Evidence   |
|--|---|
|  | <ul> <li>Although the body of low-quality RCTs suggest that steroid injection is inferior to platelet<br/>rich plasma injections at reducing pain in the short and long-term, no high quality studies<br/>currently exist.</li> </ul> |
|  | <ul> <li>Only one low-quality RCT compared the effectiveness of steroid injection to radiation<br/>therapy.</li> </ul>  |
| What is the evidence for the safety of steroid injections into the plantar fascia? | Steroid injection is associated with increased risk of rupture of the plantar fascia (Grade of Recommendation: D, based on one AQ case-control study)   |
| What is the evidence for differences in effectiveness if imaging is used?          | Evidence of Effectiveness by Guidance Method  There is no difference in pain outcome for steroid injections delivered with ultrasound or palpation guidance (Grade of Recommendation B: based on one HQ RCT)                          |
| Does the evidence report any information about cost effectiveness?                 | No systematic review, experimental study, or observational study identified within this search provided an economic analysis of steroid injection in the treatment of plantar fasciitis/fasciopathy.                                  |





# 1. Background

#### 1.1 Objective of this Review

The objective of this review is to synthesise the evidence related to the effectiveness of injection of steroid, with or without local anaesthetic, to the plantar fascia as a form of interventional pain management for plantar heel pain arising from plantar fasciitis (PF) or plantar fasciopathy. This review will carry out a systematic review of the best available research evidence. This review aims to answer the following research questions:

- a) What is the evidence for the effectiveness of steroid injections to the plantar fascia in relieving plantar heel pain?
- b) What is the evidence for the effectiveness of steroid injections to the plantar fascia in improving functional outcomes in patients?
- c) What is the evidence for the safety of steroid injections to the plantar fascia?

The injection of corticosteroid to the plantar fascia has historically been regarded as an effective treatment for plantar fasciitis, either as a first-line treatment or more commonly following an unsatisfactory response to conservative treatments such as stretching exercises, splinting and walking casts, non-steroidal anti-inflammatory drugs, heel pads, or orthotic devices (Kirkland & Beeson, 2013; Lim, How, & Tan, 2016; Uden et al, 2011).

Plantar fasciitis (or plantar fasciopathy) is one of the most common disorders of the foot (Lee & Ahmad, 2007), causing pain and tenderness under the heel that is characteristically worse during the first steps on getting up from bed in the morning or after periods of inactivity, with pain exacerbated by prolonged standing or walking (Diaz-Llopis et al., 2012). It is estimated that plantar fasciitis will affect 15% of adults within their lifetime and accounts for approximately 25% of all foot injuries related to running (Kirkland & Beeson, 2013). Although plantar fasciopathy typically resolves without intervention, resolution of pain and associated disability can take up to 18 months (Kirkland & Beeson, 2013), highlighting a need for intervention in the short to medium term to relieve pain and improve function.

1.2
Description of the Intervention

Although its aetiology is not well understood, it is generally recognised that the causes of plantar fasciitis are multifactorial and involve both inflammatory and degenerative processes, although the relative extent to which these processes affect the disease process is debated. It is generally recognised that over time, mechanical overload and biomechanical abnormalities of the foot contribute to repetitive micro trauma and micro tears, which impair normal healing processes thereby resulting in a chronic inflammatory reaction (Kirkland & Beeson, 2013).

Steroid injections to the plantar fascia have commonly been used in recalcitrant cases of plantar fasciitis, where conservative therapies have failed to bring about relief. Uncertainty regarding the mechanisms of action of steroid injections reflect a broader uncertainty regarding the physiological processes underlying plantar fasciopathy, although likely mechanisms of action involve limiting capillary dilation, reducing the permeability of vascular structures, reducing prostaglandin release, inhibiting fibroblast proliferation, and inhibiting the expression of group substance proteins (Kirkland & Beeson, 2013).



Although the choice of injectate varies, methylprednisolone is often used because of its solubility and short/medium duration of action (Gross & Lin, 2012). Although steroids with greater solubility (e.g. methylprednisolone and dexamethasone phosphate) have a shorter duration of action when compared to less soluble steroids, they are also thought to reduce the risk of post-injection flare and soft tissue atrophy (McMillan et al., 2012). Fluorinated steroids (such as the relatively insoluble triamcinolone) are thought to have greater anti-inflammatory action, but are also associated with collagen degradation and increased risk of plantar fascia rupture (McMillan et al., 2012). Local anaesthetic is typically added to steroid injectate because of its ability to provide temporary pain relief and dilute crystal deposits from acetate-steroids (McMillan et al., 2012).

After localisation of the point of maximal tenderness, injection is typically made from the medial side, perpendicular to the skin and past the midline of the width of the plantar foot, with the needle point under the point of maximum tenderness. The site of injection depends on the site of pain, although the most common site is the medial calcaneal tuberosity. Injection can be made either under ultrasound guidance or by palpation of the plantar fascia (Gross & Lin, 2012). Injection may also be performed to the posterior heel, parallel to the heel pad (Ball et al., 2013), or via a medial oblique approach (McMillan et al., 2012).

The injection technique used can either involve evenly injecting the injectate across the middle third of the width of the foot as the needle is withdrawn (Gross & Lin, 2012) or by using a peppering technique that involves multiple penetrations of the fascia with a single skin portal (Guner et al., 2013).

Steroid injections to the plantar fascia are usually associated with transient localised pain at the injection site (Kalaci et al., 2009; Porter & Shadbolt, 2005; Uden et al., 2011), with evidence of less common minor side effects of abscess formation (Buccilli et al., 2005) and infection (Patil et al., 2015).

Fascial rupture and fat pad atrophy are two serious complications that may result from injection to the plantar fascia. Fascial rupture has previously been identified in as many as 10% of patients injected with steroid (Acevedo & Beskin, 1998), although it is argued elsewhere that incidence is much lower (2.4%) and injection is a contributing factor in combination with other coexisting factors such as obesity (Kim et al., 2010). Triamcinolone in particular has been implicated in predisposing tendors to spontaneous rupture through suppression of tencorte

coexisting factors such as obesity (Kim et al., 2010). Triamcinolone in particular has been implicated in predisposing tendons to spontaneous rupture through suppression of tenocyte cellular activity and collagen production (Wong et al., 2004). Fat pad atrophy can arise from mis-injection into the fat pad resulting in reduced subcalcaneal cushioning and predisposing the plantar fascia to further injury, although its risk is greatly reduced with ultrasound-guided injection (Tsai et al., 2000). Other reported serious complications have some from case studies

injection (Tsai et al., 2000). Other reported serious complications have come from case studies and include calcaneal osteomyelitis (Gidumal & Evanski, 1985), lateral plantar nerve palsy (Snow et al., 2005), and peripheral nerve injury (Speed, 2007).

It has been recommended that ultrasound guidance should be utilised to improve injection accuracy, reducing the need for repeat injections and thus reducing the risk of plantar fascia rupture and plantar fat pad atrophy (Hall, 2013; Tatli & Kapasi, 2009; Tsai et al., 2000).

1.3 Safety/Risk



# 2. Methodology

| 2.1<br>Review question | What is the effectiveness of steroid injection to the plantar fascia with or without local anaesthetic?  |  |  |  |  |
|------------------------|--|--|--|--|--|
| 2.2<br>Methods         | A systematic review of published research literature was undertaken to provide a synthesis of the currently available research evidence related to the effectiveness of steroid injections to the plantar fascia with or without local anaesthetic as a form of interventional pain management for plantar fasciitis/fasciopathy. A systematic and rigorous search strategy was developed to locate all published and accessible research evidence. The evidence base for this review included research evidence from existing systematic reviews, meta-analyses, and high-level primary research (randomised controlled trials and prospective cohort studies). Where no systematic reviews, randomised controlled trials, or prospective cohort studies were located, other primary study designs (excluding commentary and expert opinion) were considered. |  |  |  |  |
|                        | language articles usi  | eloped using a standard PICO structure, shown in Table 1. Only Englishing human participants were included in this review.  Le 1: Criteria for considering studies in the review  Humans diagnosed with plantar fasciitis/fasciopathy or plantar heel pain  Steroid injection to the plantar fascia with or without local anaesthetic as |  |  |  |
|                        | Intervention  Comparator   | a form of interventional pain management   |  |  |  |
| 2.3<br>Search strategy | Outcomes   | <ul> <li>Any active treatment or placebo</li> <li>Pain-related primary outcomes</li> <li>Functional outcomes (range of motion, reduction of disability, return to work, quality of life)</li> <li>Safety and risk</li> <li>Relationship to Imaging</li> <li>Best practice recommendations</li> <li>Cost effectiveness</li> </ul>         |  |  |  |
|                        | A combination of sea<br>the following databa   | arch terms (shown in Table 2) were used to identify and retrieve articles in ses:  |  |  |  |
|                        | OVID      EMBASI     MEDLIN     MEDLIN     AMED,   | • The Cochrane Library   |  |  |  |



| Table | <b>3</b> . | C      | L     | f + h - |        |
|-------|------------|--------|-------|---------|--------|
| rabie | Z:         | Search | terms | tor the | review |

| Search terms 1 | Search terms 2 | Search terms 3   | Search terms 4   |
|----------------|----------------|--|--|
| • Pain         | • Injection    | Heel     Plantar Fasciitis     Heel spur     Plantar aponeurosis | <ul> <li>Steroid</li> <li>Betamethasone</li> <li>Dexamethasone</li> <li>Fluocortolone</li> <li>Methylprednisolone</li> <li>Paramethasone</li> <li>Prednisolone</li> <li>Prednisone</li> <li>Triamcinolone</li> <li>Hydrocortisone</li> <li>Cortisone</li> <li>Methandrostenolone</li> <li>Stanozolol</li> <li>Methenolone</li> <li>Oxymetholone</li> <li>Oxandrolone</li> <li>Nandrolone</li> <li>Diflucortolone</li> <li>Fluprednisolone</li> </ul> |

The titles and abstracts identified from the above search strategy were assessed for eligibility by the *i*CAHE researchers. Full-text copies of eligible articles were retrieved for full examination. Reference lists of included full-text articles were searched for relevant literature not located through database searching. The search string used in the Medline search is provided in Appendix 1.

#### **Inclusion Criteria**

- Study Types: systematic reviews, all primary research designs (randomised controlled trials (RCTs), controlled clinical trials (CCTs), cohort studies (prospective or retrospective), case-control studies, case studies or case series.
- Participants: patients clinically diagnosed with plantar fasciitis/fasciopathy or plantar heel pain
- Intervention: steroid injections, with or without local anaesthetic, delivered to the plantar fascia
- Controls: any active treatment, placebo, or no intervention control
- Outcomes: pain relief (primary), functional outcomes, safety, and risk (secondary)
- Publication criteria: English language, published in peer reviewed journal

#### **Exclusion criteria**

- Studies only available in abstract form (e.g. conference presentations)
- Grey literature and non-English language material
- Studies involving healthy volunteers or experimentally induced pain
- Studies on interventions targeting heel pain but not involving injections delivered to the planta fascia





# 2.5 Critical Appraisal

The SIGN (Scottish Intercollegiate Guidelines Network) checklist specific to the study design of the included studies was used to assess the methodological quality of the included studies (Appendix 2). The SIGN checklist asks a number of questions with yes, no, can't say or not applicable as responses with the appraiser giving an overall rating of quality, based on the responses to questions of either high quality (++), acceptable (+), low quality (-) or unacceptable/rejected. As there is no SIGN checklist for case studies these study designs will not be quality scored. Each study was graded for overall methodological quality using the SIGN levels of evidence model.

# 2.6 Data Extraction

Data were extracted from the identified publications using a data extraction tool that was specifically developed for this review. The following information were extracted from individual studies:

- Evidence source (author, date, country)
- Level of evidence
- Characteristics of participants
- Interventions (type of steroid, dose, approach, use of anesthetic)
- Comparison treatment (if relevant)
- Outcome measures
- Results and study conclusion

As described, for this review each study was graded for overall methodological quality using the SIGN checklist specific to the study design of the included studies.

Recommendations from the literature were made and scored according to a modification of the SIGN Evidence Grading matrix (see Table 3). The modification was to add levels 1 and 2 to differentiate between the 1+ and 1-, 2+ and 2- levels of evidence.

Table 3: Modified SIGN Evidence Grading Matrix

### 2.7 Data Synthesis

| Level | s of scientific evidence  |
|-------|---|
| 1++   | High-quality meta-analyses, high-quality systematic reviews of clinical trials with very little risk of bias  |
| 1+    | Well-conducted meta-analyses, systematic review of clinical trials or well-conducted clinical trials with low risk of bias  |
| 1     | Meta-analyses, systematic review of clinical trials or clinical trials with a moderate (acceptable) level risk of bias.   |
| 1-    | Meta-analyses, systematic reviews of clinical trials or clinical trials with high risk of bias.   |
| 2++   | High-quality systematic reviews of cohort or case and control studies; cohort or case and control studies with very low risk of bias and high probability of establishing a causal relationship |
| 2+    | Well-conducted cohort or case and control studies with low risk of bias and moderate probability of establishing a causal relationship  |
| 2     | Cohort or case and control studies with moderate risk of bias and potential risk that the relationship is not causal.   |
| 2-    | Cohort or case and control studies with high risk of bias and significant risk that the relationship is not causal.   |
| 3     | Non-analytical studies, such as case reports and case series.   |
| 4     | Expert opinion.   |



To standardise the strengths of recommendations from the extensive literature used for this review a structured system was developed to incorporate a number of quality measures. Four measures were selected as important variables for the assessment of strength of recommendations from the primary and secondary research sources. These were

- a) Combination of data via meta-analysis
- b) Quality of systematic review/trials
- c) Number of RCTs
- d) Consistency of the evidence

A scoring system was developed, based on a 0 and 1 score for each of these variables.

- 1. Combination of data via meta-analysis: Yes = 1, No = 0
- 2. Quality of systematic review: HQ/AQ (+) =1, LQ(0)/R = 0
- 3. Number of RCTs:  $\geq$  5RCTs = 1, < 5=0
- 4. Consistency: ≥ 75% agreement = 1, < 75% agreement = 0

This allowed for a maximum potentials core of 4 and a minimum score of 0, which reflected a measure of the evidence strength across a range of studies. The resultant score was transferred to the SIGN Evidence Grading matrix

| Total Score | SIGN Evidence Grading matrix score |
|-------------|------------------------------------|
| 4           | 1++                                |
| 3           | 1+                                 |
| 2 /         | 1                                  |
| 1/0         | 1-                                 |

Recommendations were graded according to the Scottish Intercollegiate Guidelines network (SIGN) Grades of Recommendations (Table 4).

Table 4: Scottish Intercollegiate Guidelines network (SIGN) Grades of Recommendations

| Grades of Recommendations |  |  |  |  |  |
|---------------------------|--|--|--|--|--|
| Α                         | At least one meta-analysis, systematic review or clinical trial classified as 1++ and directly applicable to the target population of the guideline, or a volume of scientific evidence comprising studies classified as 1+ and which are highly consistent with each other. |  |  |  |  |
| В                         | A body of scientific evidence comprising studies classified as 2++, directly applicable to the target population of the guideline and highly consistent with each other, or scientific evidence extrapolated from studies classified as 1++ or 1+.                           |  |  |  |  |
| С                         | A body of scientific evidence comprising studies classified as 2+, directly applicable to the target population of the guideline and highly consistent with each other, or scientific evidence extrapolated from studies classified as 2++.                                  |  |  |  |  |
| D                         | Level 3 or 4 scientific evidence, or scientific evidence extrapolated from studies classified as 2+  |  |  |  |  |

2.8
Grades of
Recommendations

#### 3. Results

The search yielded 657 articles in total. Following removal of duplicates 345 articles were identified for screening of title and abstract. After scrutiny, 270 articles were excluded for failing to meet the inclusion criteria, leaving 75 studies for inclusion in this review. Figure 1 illustrates the process involved in study selection.




Figure 1: Flow chart of search results

Nine systematic reviews (SR) met the inclusion criteria, including four high-quality SRs (Crawford et al. 2002; Crawford & Thomson, 2003; Tsikopoulos et al., 2016; Uden et al., 2011), two adequate quality reviews (Atkins et al., 1999; Z. Li et al., 2015), and three low quality reviews (Ang, 2015; Lafuente Guijosa et al., 2007; Tatli & Kapasi, 2009). The Cochrane SR by Crawford and colleagues (Crawford & Thomson, 2003) was included in this review because of its quality; however, it is recognised that this review was withdrawn in 2010 because it was considered 'substantially out-of-date' by the Cochrane Bone, Joint and Muscle Trauma Editorial

Group (Crawford & Thomson, 2010).

3.2 Quality of the Evidence

3.1

**Evidence Sources** 

Randomised controlled trials (RCTs) were only included if they were published between 2005 and 2016 and were not included in the SRs above. This left four high quality studies (Celik et al., 2016; Eslamian et al., 2016; Li et al., 2014; Mahindra et al., 2016), one adequate quality study (Mardani-Kivi et al., 2015), 13 low quality studies (Ahmed et al, 2013; Al-Bluwi et al. 2011; Biswas et al., 2011; Canyilmaz et al., 2015; Chen et al., 2013; Hanselman et al. 2015; Jain et al., 2015; Monto, 2014; Saba & El-Sherif, 2016; Tsai et al., 2006; Yesiltas et al., 2015; Yucel et al., 2010; Yucel et al. 2009), and five studies that were rejected because of insufficient reporting on which to base an assessment of quality (Motififard et al., 2008; Mulherin & Price, 2009; Narula et al., 2014; Omar et al., 2012; Tiwari & Bhargava, 2013).





No prospective or retrospective cohort studies were located, although one case-control study was located and included within this review (Lee et al., 2014). Other observational studies employed lower level designs (case studies or case series) and were not included within this review.

Full details of the quality appraisal of individual studies can be found in appendices 3, 4, and 5 (critical appraisal for systematic reviews, randomised controlled trials, and case-control studies).

All 11 included systematic reviews examined heel pain as the primary outcome, with some also reporting on outcomes related to heel function (Atkins et al., 1999) or anatomical changes to the plantar fascia (Ang, 2015; Atkins et al., 1999; Li et al., 2015). The number of included studies in each review ranged from one to 10 randomised controlled trials, comparing steroid injection against placebo or alternative treatments for plantar fasciitis that included exercise and stretching, insoles, heel pads or orthotic devices, night splints, autologous blood, botulinum toxin type A, and electro hydraulic/extracorporeal shock wave therapy. The strength of evidence (according to SIGN levels of evidence rating) within each of these reviews ranged from 1- to 1+. Only two SRs provided a meta-analysis of results (Li et al., 2014; Tsikopoulos et al., 2016).

3.3 Findings

Nineteen RCTs published between 2006 and 2016 that were not included in the reported SRs and not rejected because of poor quality were also reviewed. Included studies compared steroid injection to placebo injection, oral non-steroidal anti-inflammatory drugs, physical therapies, orthotic devices, botulinum toxin, cryopreserved human amniotic membrane, extracorporeal shockwave therapy, autologous blood or platelet-rich plasma injection, radiation therapy, and miniscalpel needle release treatment. All studies reported on outcomes of heel pain, with some also reporting on functional and anatomical outcomes. One study compared the effectiveness of different steroid types (Ahmed et al., 2013), four examined differences in outcome according to guidance method used (Chen et al., 2013; Saba & El-Sherif, 2016; Tsai et al., 2006; Yucel et al., 2009)

Full details of individual studies can be found in Appendix 6 (full data extraction).





#### **Systematic Reviews**

#### Steroid Injection versus Placebo

#### Li et al., (2015)

Li et al. (Li et al., 2015) conducted a meta-analysis of four RCTs (N = 289) comparing steroid injection with placebo injection on outcomes of heel pain and plantar fascia thickness for patients diagnosed with plantar fasciitis (PF). Use of steroid injection was found to produce significant improvements in pain compared to placebo at one month; however, there was no significant difference at either two or three months post-treatment. No significant difference in plantar fascia thickness was observed for treatment with steroid injection or placebo. Thus it was concluded that steroid injection is effective at reducing pain in the short-term, with a loss of therapeutic effectiveness at two and three months.

| Study           | QS     | Conclusions  | Level of Evidence |
|-----------------|--------|--|-------------------|
| Li et al (2015) | AQ (+) | <ul> <li>Corticosteroids resulted in significant improvement in pain compared to placebo after one month; however there was no significant difference after two or three months.</li> <li>No significant difference was found in plantar fascial thickness for those treated with steroid or placebo.</li> </ul> | 1                 |

# 3.4 Outcome Measures – Pain and Function

#### Tatli & Kapasi (2009)

In a low quality systematic review by Tatli & Kapasi (Tatli & Kapasi, 2009), a single RCT by Crawford et al. (Crawford et al, 1999) (N=91) was examined, finding that injection with prednisolone (with anaesthetic +/- tibial block) was significantly more effective than injection with anaesthetic alone at one month but not three months post-treatment. The authors concluded that steroid injections are effective at providing short-term pain relief; however, it was recognised that the review was based on studies identified through a single database search and was unlikely to have engaged with the evidence base in a comprehensive way.

| Study                 | QS       | Conclusions  | Level of<br>Evidence |
|-----------------------|----------|--|----------------------|
| Tatli et al<br>(2009) | 1 10 (-) | The single RCT examined demonstrated significant         |                      |
|                       |          | improvement in pain with steroid injection at one month, | 1-                   |
|                       |          | but not at 3 months following treatment.                 |                      |

#### Lafuente Guijosa et al., (2007)

In a low-quality systematic review by Lafuente Guijosa et al. (Lafuente Guijosa et al., 2007), one RCT by Crawford et al. (Crawford et al., 1999) was identified comparing steroid injection to placebo. The authors concluded that steroid injection was effective in reducing heel pain, but only on the short-term and to a limited extent.

Poor review reporting meant that it was difficult to determine the level of rigour applied to the review process and the characteristics of included studies.





| Study                               | QS     | Conclusions  | Level of<br>Evidence |  |
|-------------------------------------|--------|--|----------------------|--|
| Lafuente<br>Guijosa et al<br>(2007) | LQ (-) | Steroid injections are useful in reducing heel pain, but only on the short-term and to a limited extent. | 1-                   |  |

#### Crawford et al., (2003)

As part of a broader Cochrane systematic review examining the effectiveness of interventions for treating plantar heel pain, Crawford et al. (2003) examined five RCTs (N = 292) comparing the effectiveness of steroid injection against placebo and alternative treatment options of heel pads and custom-made orthoses. In comparison to placebo, steroid injection was found to be no more effective or only effective at reducing heel pain in the short term.

| Study                    | QS         | Conclusions  | Level of<br>Evidence |
|--------------------------|------------|--|----------------------|
| Crawford et al<br>(2003) | HQ<br>(++) | <ul> <li>There is limited evidence for the effectiveness of local steroid therapy.</li> <li>Steroid injections appear to be useful only in the short term and only to a small degree.</li> </ul> | 1                    |

#### Steroid Injection versus Alternative Treatments

#### Tsikopouls et al., (2016)

Tsikopouls et al. (2016) conducted a high quality systematic review/meta-analysis (MA) of RCTs (N = 140) comparing the effect of steroid injections versus autologous whole blood injection on heel pain in patients diagnosed with PF or epicondylopathy (this review considers only the former clinical population). The authors concluded that although steroid injection was marginally more effective (reaching statistical significance) at 2-6 weeks after treatment, there was no significant difference at 24-26 weeks after treatment. Caution was advised by the authors in interpreting these findings given the risk of bias associated with included studies, the inclusion of only three RCTs, and the clinical diversity observed within included studies.

| Study          | QS   | Conclusions   | Level of<br>Evidence |
|----------------|------|---|----------------------|
|                |      | In the short-term (2-6 weeks after treatment), steroid      |                      |
| Tsikopoulos et | HQ   | injections were marginally more effective in relieving pain |                      |
| al (2016)      | (++) | that autologous whole blood injection. However, there was   | 1                    |
|                |      | no significant difference at 24-26 weeks after treatment.   |                      |

#### Ang et al., (2015)

Although considered to be of low-quality because of questions regarding the rigour of the review process, Ang et al. (Ang et al, 2015) provided a SR of 10 RCTs (N = 622) comparing steroid injection to various alternative treatments. All included studies demonstrated improvement in pain and/or plantar fascia thickness with steroid injection.





In comparison to other treatment modalities, corticosteroid injection was similar in effectiveness to physiotherapist-led exercise, more effective than use of silicone insoles, less effective than injection with botulinum toxin A, and more effective than injection with autologous blood. There was also no difference in effectiveness with ultrasound or palpation-guided approaches. The authors acknowledged that further study is required to provide conclusive evidence for the comparative effectiveness of these treatments.

| Study               | QS     | Conclusions   | Level of<br>Evidence |
|---------------------|--------|---|----------------------|
| Ang et al<br>(2015) | LQ (-) | <ul> <li>In comparison to other treatment modalities, steroid injection was similar in effectiveness to physiotherapist-led exercise, more effective than use of silicone insoles, less effective than injection with botulinum toxin A, and more effective than injection with autologous blood.</li> <li>There was no difference in effectiveness between ultrasound and palpation-guided injections or choice of steroid injection.</li> </ul> | 1-                   |

#### Uden et al., (2011)

Uden et al. (Uden et al., 2011) provided a systematic review including two RCTs, one comparing steroid injection against electro hydraulic extracorporeal shock wave therapy and stretching exercises, and the other comparing steroid injection against autologous blood injection. Both studies reported significantly greater reductions in heel pain with steroid injection in the short term, although long-term effectiveness was similar for steroid injection and the alternative treatments.

| Study                | QS         | Conclusions   | Level of<br>Evidence |
|----------------------|------------|---|----------------------|
| Uden et al<br>(2011) | HQ<br>(++) | The two RCTs reviewed demonstrated short-term improvements in pain for corticosteroid injections versus treatments of electro hydraulic shock wave therapy or stretching exercises only or autologous blood injection | 1-                   |

#### Lafuente et al., (2007)

In a low-quality systematic review by Lafuente et al. (Lafuente et al., 2007), four RCTs (N = 273) were identified comparing steroid injection to orthotic devices/heel pads. The authors concluded that steroid injection was effective in reducing heel pain, but only on the short-term and to a limited extent.

Poor reporting meant that it was difficult to determine the level of rigour applied to the review process and the characteristics of included studies.

| Study          | QS     | Conclusions   | Level of<br>Evidence |
|----------------|--------|---|----------------------|
| Lafuente et al | LQ (-) | Steroid injections are useful in reducing heel pain, but only | 1-                   |
| (2007)         | LQ (-) | on the short-term and to a limited extent.                    | 1-                   |





#### Crawford & Thomson (2003)

As part of a broader Cochrane systematic review examining the effectiveness of interventions for treating plantar heel pain, Crawford & Thomson (2003). The authors examined five RCTs (N = 292) comparing the effectiveness of steroid injection against placebo and conservative treatment options of heel pads and custom-made orthoses. The relative effectiveness of steroid injections compared to heel pads and orthoses was considered to be unclear.

| Study                    | QS         | Conclusions   | Level of<br>Evidence |
|--------------------------|------------|---|----------------------|
| Crawford et al<br>(2003) | HQ<br>(++) | <ul> <li>There is limited evidence for the effectiveness of local corticosteroid therapy.</li> <li>Steroid injections appear to be useful only in the short term and only to a small degree.</li> </ul> | 1                    |

#### Crawford et al., (2002)

An earlier systematic review by Crawford et al. (Crawford et al., 2002) examined three RCTs (N = 116), and similar to the later review (Crawford & Thomson, 2003) found conflicting results regarding the effectiveness of steroid injection compared to insole or heel pads in reducing heel pain. The authors concluded that there was limited evidence available to determine the true effectiveness of steroid injection compared with placebo or in comparison to alternative treatments and that high quality randomised studies were required.

| Study                 | QS         | Conclusions  | Level of<br>Evidence |
|-----------------------|------------|--|----------------------|
| Crawford et al (2002) | HQ<br>(++) | <ul> <li>Conflicting results, with one study found significant improvements in pain with steroid injection compared to insole and another found no difference between steroid injections compared to heel pads.</li> <li>The effectiveness of steroid injection has not been demonstrated against placebo treatment.</li> <li>In all trials, improvement in heel pain was noted in both treated and non-treated groups.</li> </ul> | 1-                   |

#### Atkins et al., (1999)

In a review of 3 RCTs (N = 116) by Atkins et al. (Atkins et al., 1999), one included study found improvements in pain outcome for steroid inject alone, compared with steroid and insole intervention, whereas two other studies found no benefit of steroid injection compared to heel pads or injection within saline. The authors were unable to produce robust evidence of effectiveness for steroid injection or alternative treatments for PF owing to the poor methodological quality of included studies.

| Carralia | 00 | Conducione  | Level of | l |
|----------|----|-------------|----------|---|
| Study    | QS | Conclusions | Evidence |   |





| Atkins et al           |        | Given overall poor methodological quality of studies, it is |    |
|------------------------|--------|---|----|
| Atkins et al<br>(1999) | AQ (+) | not possible to produce robust evidence of effectiveness of | 1- |
| (1999)                 |        | any treatment for plantar fasciitis.                        |    |

#### **Randomised Controlled Trials**

The following RCTs were not included in the previously reported SRs.

#### Steroid Injection versus Placebo

#### Mahindra et al., (2016)

Mahindra et al (Mahindra et al., 2016) compared palpation-guided injection of 40mg methylprednisolone (use of anaesthetic not reported) against placebo injection in 75 patients that had failed to respond to conservative therapy for three or more months. Steroid injection resulted in significant improvements over placebo in pain and heel function at three weeks and three months post-treatment.

| Study          | QS   | Conclusions  |
|----------------|------|--|
| Mahindra et al | HQ   | Local injection of steroid (or platelet rich plasma) is an effective |
| (2016)         | (++) | treatment option for chronic plantar fasciitis up to 3 months        |

#### Al-Bluwi et al., (2011)

In a low-quality RCT, Al-Bluwi et al. (Al-Bluwi et al., 2011) compared the effectiveness of a specific orthotic device (EZStep), physiotherapy exercises, and palpation-guided steroid injection (type not specified) in improving pain in 198 patients with clinically diagnosed PF. All three treatment groups were also provided with NSAIDs as part of their treatment regime. Steroid injection was found to be significantly less effective than EZStep orthotic device at 24 weeks post-treatment, but more effective than physiotherapy. Although this study was not intended to study the role of steroid injection in PF; the authors noted that the steroid (and NSAID) group fared significantly better than physiotherapy (and NSAID) group.

| Study                    | QS     | Conclusions  |  |
|--------------------------|--------|--|--|
| Al-Bluwi et al<br>(2011) | LQ (-) | Steroid injection (and NSAID) was found to be significantly less effective |  |
|                          |        | than EZStep orthotic device (and NSAID) at 24 weeks post-treatment, but    |  |
|                          |        | more effective than physiotherapy (and NSAID).                             |  |

#### **Physical Therapies**

#### Celik et al., (2016)

Celik et al (Celik et al., 2016) compared palpation-guided injection of 40mg methylprednisolone with anaesthetic to joint mobilisation and stretching exercises in 43 patients with chronic PF. Pain and functional outcomes improved at three, six, and 12 weeks follow-up for both groups, with significantly better results for steroid injection at all-time points. However, there were no significant differences between groups at one year for pain and functional outcomes. Therefore, injection with methylprednisolone was shown to be more effective in the short term





at improving pain and function compared to joint mobilisation and stretching, although neither was more effective at one year following treatment.

| Study       | QS   | Conclusions  |  |  |
|-------------|------|--|--|--|
|             |      | While both groups achieved significant improvements at the three, six, |  |  |
|             |      | and 12 week follow-ups, the steroid injection group demonstrated       |  |  |
| Celik et al | HQ   | better outcomes at all three time points.                              |  |  |
| (2016)      | (++) | Improvements in pain and functional outcomes were sustained for the    |  |  |
|             |      | joint mobilisation and stretching group for a period of time ranging   |  |  |
|             |      | from 12 weeks to 1 year, but not for the steroid injections.           |  |  |

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

#### Biswas et al., (2011)

One low-quality RCT (Biswas et al., 2011) examined the effectiveness of palpation-guided 40mg methylprednisolone with anaesthetic versus NSAID in the first-line treatment of 120 patients with recent-onset (< 3 months) PF. Pain was significantly lower for the steroid injection group at all-time points (one, two, four, and eight weeks post-treatment) compared with NSAID and the recurrence of heel pain was significantly lower in the steroid group (6/60 patients for steroid injection vs 33/60 patients for NSAID). Thus it was concluded that local injection of steroid is more effective in the first-line treatment of PF than oral NSAIDs.

| Study        | QS     | Conclusions  |
|--------------|--------|--|
| Biswas et al | LQ (-) | Local injection of steroid is more effective in the treatment of plantar |
| (2011)       |        | fasciitis than oral NSAIDs.  |

Extracorporeal Shock Wave Therapy (ESWT)

#### Eslamian et al., (2016)

Eslamian et al (Eslamian et al., 2016) compared palpation-guided injection of 40mg methylprednisolone with anaesthetic to radial ESWT in 40 patients non-responsive to conservative treatment of PF for two or more months. At one and two months after treatment, pain and foot function improved significantly for both groups, with no significant between group differences, and no significant difference in satisfaction with pain relief between groups.

| Study                    | QS         | Conclusions  |
|--------------------------|------------|--|
|                          | HQ<br>(++) | Both steroid injection and ESWT resulted in improvement in pain and    |
|                          |            | functional ability two months after treatment, with neither being      |
| Eslamian et al<br>(2016) |            | significantly more effective than the other. Although inter-group      |
|                          |            | differences were not significant, foot function was improved more with |
|                          |            | ESWT and patients were more satisfied with ESWT, thus shockwave        |
|                          |            | therapy seems a safe alternative for management of chronic plantar     |
|                          |            | fasciitis  |





#### Mardani-Kivi et al., (2015)

Mardani-Kivi et al. (Mardani-Kivi et al., 2015) compared palpation-guided injection of 40mg methylprednisolone to EWST, this time in 84 patients with acute (pain lasting less than 6 weeks) PF. Pain intensity significantly improved in both groups compared to baseline at all-time points (three, six, and 12 weeks), with significantly greater improvement in favour of steroid injection. Treatment failure was observed in 14.7% of cases for steroid injection and 55.9% of cases for ESWT. These findings led the authors to conclude that steroid injection is more effective than ESWT in the initial treatment of PF.

| Study                      | QS     | Conclusions  |
|----------------------------|--------|--|
| Mardani-Kivi et<br>al.2015 | AQ (+) | Both ESWT and steroid injection can be used as initial treatment options |
|                            |        | for treating patients with acute plantar fasciitis; however, steroid     |
|                            |        | injection is more effective  |

#### Steroid Injection versus alternative treatments (Invasive)

Platelet Rich Plasma Injection

#### Mahindra et al., (2016)

Mahindra et al (Mahindra et al., 2016) compared palpation-guided injection of 40mg methylprednisolone (use of anaesthetic not reported) against platelet rich plasma injection or placebo injection in 75 patients that had failed to respond to conservative therapy for three or more months. There were significant improvements in pain and heel function score at three weeks and three months for both treatment groups, but not for placebo. There were no significant differences between platelet rich plasma injection and steroid injection, with the exception of significantly better heel function in the platelet rich plasma group at three months. This led to the author's concluding that platelet rich plasma injection is as effective, if not more effective, than corticosteroid injection in treating chronic PF.

| Study          | QS   | Conclusions   |
|----------------|------|---|
|                |      | Local injection of platelet rich plasma or steroid is an effective        |
| Mahindra et al | HQ   | treatment option for chronic plantar fasciitis.                           |
| (2016)         | (++) | Platelet-rich plasma injection is as effective if not more effective than |
|                |      | steroid injection in treating chronic plantar fasciitis                   |

#### Jain et al., (2015)

A low-quality study by Jain et al. (Jain et al., 2015) compared palpation-guided injection of 40mg triamcinolone with anaesthetic to PRP in 60 patients with plantar heel pain lasting greater than 12 months. At three months post-injection, both steroid and PRP groups demonstrated significant improvements across all outcomes related to heel pain and foot function, with no significant between-group differences. At six months there was no significant difference between groups for any outcome. At 12 months, all outcomes were significantly





better for PRP than for steroid injection, with the authors concluding that PRP has a better and more durable effect than steroid injection.

| Study      | QS     | Conclusions  |
|------------|--------|--|
|            | LQ (-) | PRP is as effective as steroid injection at achieving symptom relief at 3    |
| Jain et al |        | and 6 months after injection, for the treatment of plantar fasciitis, but    |
| (2015)     |        | unlike steroid, its effect does not wear off with time. At 12 months, PRP is |
|            |        | significantly more effective than steroid.                                   |

#### Monto (2014); Tiwari & Bhargava (2013)

Two other low-quality studies (Monto, 2014; Tiwari & Bhargava, 2013) also examined the effectiveness of PRP injection, comparing this to injection of 40mg methyl prednisone with anaesthetic under US (Monto, 2014) or radiographic (Tiwari & Bhargava, 2013) guidance. In their group of 40 patients that were non-responsive to conservative therapy, Monto (Monto, 2014) reported that PRP injection resulted in significantly greater improvement in foot pain and function compared with steroid injection at three, six, 12, and 24 months. In their group of 60 patients with a clinical diagnosis of PF (with various exposures to previous conservative treatments), Tiwari and Bhargava (Tiwari & Bhargava, 2013) found that PRP resulted in significantly greater pain reduction than steroid injection at one, three, and six months. Thus both authors concluded that PRP was more effective than steroid injection in the treatment of PF.

| Study        | QS     | Conclusions   |
|--------------|--------|---|
| Monto (2014) | LQ (-) | PRP injection was more effective and durable than steroid injection for |
|              |        | the treatment of chronic recalcitrant cases of PF                       |

| Study              | QS /   | Conclusions  |
|--------------------|--------|--|
| Tiwari and         |        | PRP injection is more effective than steroid injection at relieving pain |
| Bhargava<br>(2013) | LQ (-) | from PF  |
| (2013)             |        |  |

Autologous Blood Injection (ABI)

#### Yesiltas et al., (2015)

One low-quality RCT by Yesiltas et al. (Yesiltas et al., 2015) compared ABI with US-guided injection with triamcinolone in 60 patients with a diagnosis of PF. Both treatment groups resulted in significant improvements in pain at six weeks, three months, and six months, with no significant between group differences. Using US imaging, steroid injection was found to be significantly more effective at reducing heel pad thickness and diameter of the inflammation site than ABI.

| Study                    | QS     | Conclusions  |
|--------------------------|--------|--|
| Yesiltas et al<br>(2015) | LQ (-) | Intralesional steroid injection and autologous venous blood injection have comparable effectiveness in the treatment of pain with PF, although |





| steroid injection was more effective at improving heel pad thickness and |
|--|
| the diameter of the site of inflammation.                                |
|  |

Cryopreserved Human Amniotic Membrane Injection (c-hAM)

#### Hanselman et al., (2015)

A low-quality pilot RCT by Hanselman et al. (Hanselman et al., 2015) compared palpation-guided injection with 40mg methylprednisolone with anaesthetic to injection with c-hAM in 24 patients with a clinical diagnosis of PF. In the group receiving a single steroid injection, shoe fit at six weeks and general health at six weeks were statistically greater in the steroid group. In the group receiving two consecutive steroid injections (due to an inadequate response to the first injection), foot pain score at 12 weeks post-treatment was statistically greater in the c-hAM group. There was no significant difference in other variables related to heel pain or foot function at six or 12 weeks post-treatment. This led to the authors concluding that c-hAM was comparable in effectiveness to steroid injection, although further research was required to confirm the results of this pilot.

| Study                  | QS     | Conclusions  |
|------------------------|--------|--|
| Hanselman et al (2015) | LQ (-) | Cryopreserved human amniotic membrane injection may be safe and            |
|                        |        | comparable to steroid injection for treatment of PF. This is a pilot study |
|                        |        | and requires further investigation   |

Miniscalpel Needle Release Treatment

#### Li et al., (2014)

Li et al (Li et al., 2014) compared palpation-guided injection of 20mg triamcinolone with anaesthetic to miniscalpel-needle release treatment in 61 patients that had failed to respond to at least six months of conservative treatment for PF. All measures of pain (rising in morning, with activity, and overall rating) significantly improved at one, six, and 12 months for miniscalpel-needle release treatment, whereas steroid injection resulted in improvements in pain at one month, but not at six or 12 months. Miniscalpel-needle release treatment was significantly more effective than steroid injection at reducing pain at all study time points (one, six, and 12 months post-treatment).

| Study    | QS   | Conclusions  |
|----------|------|--|
| Li et al | HQ   | Miniscalpel-Needle release treatment is safe and more effective than |
| (2014)   | (++) | steroid injection in treating chronic plantar fasciitis              |

Radiation Therapy

Canyilmaz et al., (2015)





Radiation therapy (low-dose ionising radiation) was compared with palpation-guided injection of 40mg methylprednisolone in one low-quality RCT by Canyilmaz et al. (Canyilmaz et al., 2015), involving 128 patients with a clinical diagnosis of painful heel spur with pain lasting six months or more. Compared to steroid injection, radiotherapy resulted in significantly greater improvements in heel pain and foot function at three and six months after treatment.

| Study           | QS     | Conclusions   |
|-----------------|--------|---|
| Canyilmaz et al | LQ (-) | Radiation therapy is more effective at relieving pain than palpation- |
| (2015)          |        | guided steroid injection for painful heel spur                        |

#### Effectiveness by Injectate, Guidance Method, and Injection Technique

Comparison of Steroid Type

#### Ahmed et al., (2013)

One low-quality RCT by Ahmed et al. (Ahmed et al., 2013) found that palpation-guided injection with 40mg of methylprednisolone resulted in significantly greater improvements in heel pain at four, eight, and 12 weeks post-injection compared to injection with dexamethasone. Injections were performed in 60 patients with heel pain, secondary to PF, lasting 12 or more weeks with an unsatisfactory response to conservative treatments.

| Study QS Conclusions |        | Conclusions  |
|----------------------|--------|--|
| Ahmed et al          | LQ (-) | Local methylprednisolone injection is superior to local dexamethasone  |
| (2013)               |        | injection in providing short term pain relief to the patients with PF. |

Comparison of Injectate with or without Anaesthetic

No study included within this review examined the relative efficacy of steroid injection with or without anaesthetic.

Ultrasound versus Palpation-Guided Steroid Injection

#### Saba & El-Sherif (2016)

A low-quality RCT by Saba and El-Sherif (Saba & El-Sherif, 2016) compared US versus palpation-guided injection of triamcinolone with anaesthetic on pain, disability, plantar fascia thickness and echogenicity in 21 (all female) patients that were non-responsive to at least 3 months of conservative therapies. Significant improvements for all outcomes were observed in both groups, with no between group differences at either two or four weeks post-injection.

| Study                         | QS     | Conclusions  |
|-------------------------------|--------|--|
| Saba and El-<br>Sherif (2016) | LQ (-) | Ultrasound-guided and palpation-guided local corticosteroid injections |
|                               |        | were effective and successful in treatment of PF. Both techniques      |
|                               |        | improved PF clinically and ultrasonographically without statistically  |
|                               |        | significant superior results for the ultrasound-guided injection       |





#### Chen et al., (2013)

Chen et al. (Chen et al., 2013) compared the effectiveness of US (using a custom injection guidance device) versus palpation-guidance of betamethasone into the heels of 33 patients that had failed to respond to conservative therapies.

Although both US and palpation-guided steroid injection resulted in significant improvements in heel pain, tenderness threshold, and thickness of the plantar fascia, the device-assisted US-guided group demonstrated significantly improved tenderness threshold and pain score compared to the palpation-guided group. Although the authors concluded that device-assisted US-guided injection was superior to palpation-guidance, it is unclear whether US-guidance, the use of an assistive device, or both was responsible for the reported therapeutic benefit.

| Study      | QS     | Conclusions  |
|------------|--------|--|
| Chen et al | LQ (-) | Device-assisted ultrasound-guided injection for treating plantar fasciitis |
| (2013)     |        | results in better therapeutic outcomes than palpation-guided injection     |

#### Tsai et al., (2006)

Contrasting findings were presented by a low-quality RCT by Tsai et al. (Tsai et al., 2006), comparing the effectiveness of US and palpation-guided injection with betamethasone in 25 patients that were non-responsive to conservative treatment for two or more months. Between group analyses favoured US-guidance for improving tenderness threshold at two weeks, two months, and one year, for improving pain at one year, and reducing PF thickness at one year. Recurrence of heel pain was also significantly lower in the US-guided group, leading to the conclusion that US-guidance of steroid injection leads to better patient outcomes than guidance by palpation.

| Study QS Conclusions |        | Conclusions  |
|----------------------|--------|--|
| Tsai et al<br>(2006) | LQ (-) | Steroid injection can be an effective way to treat PF, and injection under |
|                      |        | sonographic guidance is associated with lower recurrence of heel pain      |

Treatment with Steroid Injection for Acute versus Chronic Plantar Fasciitis

All the high quality RCTs examined the effect of steroid injection in cases of chronic plantar fasciitis (from a minimum of two months to a minimum of 6 months plantar heel pain). Three studies examined patients that had failed to respond to conservative therapies (Eslamian 2016, Li et al 2014, Mahindra 2016) and one study did not report on exposure to prior treatments (Celik et al 2016).

#### Biswas et al., (2011); Mardani-Kivi et al., (2015)

Only two RCTs examined the use of steroid injection as a first-line treatment for acute PF. One adequate-quality RCT by Mardani-Kivi et al. (Mardani-Kivi et al., 2015) found that steroid





injection (40mg methylprednisolone with anaesthetic) and ESWT were both effective in the initial treatment of acute PF, although steroid injection was found to be significantly more effective. A low-quality RCT by Biswas et al. (Biswas et al., 2011) found that steroid injection (40mg methylprednisolone with anaesthetic) resulted in significant improvements in heel pain over NSAID when used as a first-line treatment for PF. The recurrence of heel pain was significantly lower in the steroid group (6/60 patients vs 33/60 patients for NSAID), suggesting a role for steroid injection over oral NSAIDs in the first-line treatment of acute PF.

| Study                      | QS     | Conclusions  |  |  |
|----------------------------|--------|--|--|--|
|                            |        | Both ESWT and steroid injection can be used as initial treatment options                         |  |  |
| Mardani-Kivi et<br>al.2015 | AQ (+) | for treating patients with acute plantar fasciitis; however, steroid injection is more effective |  |  |

| Study QS Conclusions   |        | Conclusions  |
|------------------------|--------|--|
| Biswas et al<br>(2011) | LQ (-) | Local injection of steroid is more effective in the treatment of plantar |
|                        |        | fasciitis than oral NSAIDs.  |

#### **Systematic Reviews**

No high quality SR identified any adverse event other than transient pain at the injection site (Crawford 2002, Crawford 2003, Tsikopoulos et al 2016, Uden et al 2011), although it was acknowledged that adverse events were not universally reported in included studies. Three of the included srs (Atkins et al., 1999; Lafuente Guijosa et al., 2007; Tatli & Kapasi, 2009) did not report on adverse events.

#### **Randomised Controlled Trials**

Four of the nine high quality RCTs that reported on the incidence of adverse events observed no adverse events with steroid injection (Celik et al., 2016; Eslamian et al., 2016; Li et al., 2014; Mahindra et al., 2016). One of the adequate-quality RCTs, did not include adverse events in their reporting (Mardani-Kivi et al., 2015).

Of the low-quality RCTs, one reported localised pain and swelling after injection, resolving within 48 hours following injection (Ahmed et al., 2013). Another reported six cases of injection site erythema, two cases of injection site infection, and two cases of plantar fascia rupture in a group of 60 patients treated with palpation-guided injection of 40mg methylprednisolone (Biswas et al., 2011). Another study reported one case of injection site infection among 64 patients treated with palpation-guided injection of methylprednisolone (Canyilmaz et al.,

No adverse events were reported in studies comparing ultrasound and palpation-guided injection with steroid (Chen et al., 2013; Saba & El-Sherif, 2016; Tsai et al., 2006; Yucel et al., 2009).


#### **Observational Studies**

2015).

One adequate quality case-control study was identified (Lee et al., 2014), which examined the risk factors for plantar fascia rupture in 286 patients previously treated for PF. Of the assessed risk factors, only steroid injection was found to be associated with plantar fascia rupture, with an odds ratio of 32.96 (95%CI: 9.724 to 111.717). Thus it was concluded that steroids should

3.5
Outcome Measures
- Safety and Risk







|                          | be used cautiously because of the risk of plantar fascia rupture. No details were provided regarding the injectate, injection technique, or guidance method used in this patient group.  |
|--------------------------|--|
| 3.6<br>Economic analysis | No systematic review, experimental study, or observational study identified within this search provided an economic analysis of steroid injection in the treatment of plantar fasciitis. |



### 4. Recommendations

#### **Evidence of Effectiveness against Placebo**

• Steroid injection to the plantar fascia appear to be effective at reducing pain in the short-term (<3months post-treatment) when compared to placebo, but fails to offer any significant benefit in the long-term (Grade of Recommendation: A, based on one HQ SR, one HQ RCT, one AQ SR, and two LQ SRs)

#### Evidence of Effectiveness compared with Conservative (non-invasive) Treatments

- Steroid injection to the plantar fascia is likely to be more effective at reducing pain in the short-term (<3months post-treatment) compared with physical therapies; however, has comparable effectiveness in the long-term (Grade of Recommendation: B, based on one HQ SR and one HQ RCT)
- Steroid injection is more effective than use of silicone insoles at reducing pain in the short-term (<3 months post-treatment), with inconsistent results for relative long-term effectiveness (Grade of Recommendation B: based on one HQ RCT)
- Steroid injection comparable to extracorporeal shockwave therapy in reducing pain in the long-term (≥3 months post-treatment), with inconsistent results regarding short-term effectiveness (Grade of Recommendation: B, based on one HQ SR, one HQ RCT, and one AQ RCT)

# Grade of Recommendations

#### Evidence of Effectiveness compared with Alternative (invasive) Treatments

- Steroid injection is superior to autologous blood injection at reducing pain in the shortterm (<3months post-treatment); however, has comparable effectiveness in the longterm (Grade of Recommendation: B, based on two HQ SRs, one LQ SR, and one LQ RCTs)
- Steroid injection is inferior to injection with botulinum toxin type A at reducing pain in the short and long-term (Grade of Recommendation B: based on one HQ RCT)
- Steroid injection is inferior to miniscalpel-needle release treatment at reducing pain in the short and long-term (Grade of Recommendation B: based on one HQ RCT)

#### **Evidence of Effectiveness by Guidance Method**

 There is no difference in pain outcome for steroid injections delivered with ultrasound or palpitation guidance (Grade of Recommendation B: based on one HQ RCT)

#### **Evidence of Adverse Events with Steroid Injection**

 Steroid injection is associated with increased risk of rupture of the plantar fascia (Grade of Recommendation: D, based on one AQ case-control study)

#### **Insufficient Body of Evidence**

- Although the body of low-quality RCTs suggest that steroid injection is inferior to platelet rich plasma injections at reducing pain in the short and long-term, as no high quality studies currently exist.
- Only one low-quality RCT compared the effectiveness of steroid injection to radiation therapy.



### 5. References

- Acevedo, J. I., & Beskin, J. L. (1998). Complications of plantar fascia rupture associated with corticosteroid injection. *Foot and Ankle International*, *19*(2), 91-97.
- Ahmed, G., Shaikh, A., & Tofique, M. (2013). Local steroid injection for treatment of planter fasciitis. Comparison between methylprednisolone and dexamethasone. *Medical Channel*, 19(4), 37-41.
- Al-Bluwi, M., Sadat-Ali, M., Al-Habdan, I., & Azam, M. (2011). Efficacy of EZStep in the management of plantar fasciitis: a prospective, randomized study. *Foot & Ankle Specialist*, *4*(4), 218-221.
- Ang, T. W. A. (2015). The effectiveness of corticosteroid injection in the treatment of plantar fasciitis. *Singapore Medical Journal, 56*(8), 423-432. doi:http://dx.doi.org/10.11622/smedj.2015118
- Atkins, D., Crawford, F., Edwards, J., & Lambert, M. (1999). A systematic review of treatments for the painful heel. *Rheumatology*, 38(10), 968-973.
- Ball, E. M., McKeeman, H. M., Patterson, C., Burns, J., Yau, W. H., Moore, O. A., . . . Taggart, A. J. (2013). Steroid injection for inferior heel pain: a randomised controlled trial. *Annals of the Rheumatic Diseases*, 72(6), 996-1002. doi:http://dx.doi.org/10.1136/annrheumdis-2012-201508
- Biswas, C., Pal, A., & Acharya, A. (2011). A comparative study of efficacy of oral nonsteroidal antiinflammatory agents and locally injectable steroid for the treatment of plantar fasciitis. *Albang Maqalat Wa Abhat Fi Altahdir Waalinas, 5*(2), 158-161. doi:http://dx.doi.org/10.4103/0259-1162.94756
- Buccilli Jr, T. A., Hall, H. R., & Solmen, J. D. (2005). Sterile abscess formation following a corticosteroid injection for the treatment of plantar fasciitis. *Journal of Foot and Ankle Surgery*, 44(6), 466-468. doi:http://dx.doi.org/10.1053/j.jfas.2005.07.020
- Canyilmaz, E., Canyilmaz, F., Aynaci, O., Colak, F., Serdar, L., Uslu, G. H., . . . Yoney, A. (2015). Prospective randomized comparison of the effectiveness of radiation therapy and local steroid injection for the treatment of plantar fasciitis. *International Journal of Radiation Oncology Biology Physics*, 92(3), 659-666. doi:10.1016/j.ijrobp.2015.02.009
- Celik, D., Kus, G., & Slrma, S. O. (2016). Joint mobilization and stretching exercise vs steroid injection in the treatment of plantar fasciitis: A randomized controlled study. *Foot and Ankle International*, *37*(2), 150-156. doi:http://dx.doi.org/10.1177/1071100715607619
- Chen, C., Chen, J., Tsai, W., Hsu, H., Chen, K., & Lin, C. (2013). Effectiveness of device-assisted ultrasound-guided steroid injection for treating plantar fasciitis. *American journal of physical medicine & rehabilitation / Association of Academic Physiatrists*, 92(7), 597-605.
- Crawford, F., Atkins, D., & Edwards, J. (2002). Interventions for treating plantar heel pain. *Foot,* 11(4), 228-250. doi:http://dx.doi.org/10.1054/foot.2002.0689



- Crawford, F., Atkins, D., Young, P., & Edwards, J. (1999). Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. *Rheumatology*, *38*(10), 974-977.
- Crawford, F., & Thomson, C. (2003). Interventions for treating plantar heel pain. *Cochrane Database of Systematic Reviews*(3), CD000416.
- Crawford, F., & Thomson, C. E. (2010). WITHDRAWN. Interventions for treating plantar heel pain. *Cochrane Database of Systematic Reviews*(1), CD000416. doi:http://dx.doi.org/10.1002/14651858.CD000416.pub2
- Diaz-Llopis, I. V., Rodriguez-Ruiz, C. M., Mulet-Perry, S., Mondejar-Gomez, F. J., Climent-Barbera, J. M., & Cholbi-Llobel, F. (2012). Randomized controlled study of the efficacy of the injection of botulinum toxin type A versus corticosteroids in chronic plantar fasciitis: results at one and six months. *Clinical Rehabilitation*, 26(7), 594-606. doi:http://dx.doi.org/10.1177/0269215511426159
- Dumbre Patil, S., Dumbre Patil, V., Abane, S., Luthra, R., & Ranaware, A. (2015). Acute Compartment Syndrome of the Foot due to Infection After Local Hydrocortisone Injection: A Case Report. *Journal of Foot and Ankle Surgery*, 54(4), 692-696. doi:http://dx.doi.org/10.1053/j.jfas.2014.02.020
- Eslamian, F., Shakouri, S. K., Jahanjoo, F., Hajialiloo, M., & Notghi, F. (2016). Extra Corporeal Shock Wave Therapy Versus Local Corticosteroid Injection in the Treatment of Chronic Plantar Fasciitis, a Single Blinded Randomized Clinical Trial. *Pain Medicine*, *17*(9), 1722-1731. doi:http://dx.doi.org/10.1093/pm/pnw113
- Gidumal, R., & Evanski, P. (1985). Calcaneal osteomyelitis following steroid injection: a case report. *Foot & Ankle, 6*(1), 44-46.
- Gross, C. E., & Lin, J. (2012). Injection Therapy in the Management of Musculoskeletal Injuries: Foot and Ankle. *Operative Techniques in Sports Medicine, 20*(2), 185-191. doi:http://dx.doi.org/10.1053/j.otsm.2012.03.014
- Guner, S., Onder, H., Guner, S., Ceylan, M., Gokalp, M., & Keskin, S. (2013). Effectiveness of local tenoxicam versus corticosteroid injection for plantar fasciitis treatment. *Orthopedics*, *36*(10), e1322-e1326.
- Hall, M. M. (2013). The accuracy and efficacy of palpation versus image-guided peripheral injections in sports medicine. *Current sports medicine reports*, *12*(5), 296-303.
- Hanselman, A., Tidwell, J., & Santrock, R. (2015). Cryopreserved human amniotic membrane injection for plantar fasciitis: a randomized, controlled, double-blind pilot study. *Foot & Ankle International*, *36*(2), 151-158.
- Jain, K., Murphy, P., & Clough, T. (2015). Platelet rich plasma versus corticosteroid injection for plantar fasciitis: A comparative study. Foot (Edinburgh, Scotland), 25(4), 235-237. doi:10.1016/j.foot.2015.08.006



- Kalaci, A., Cakici, H., Hapa, O., Yanat, A. N., Dogramaci, Y., & Sevinç, T. T. (2009). Treatment of plantar fasciitis using four different local injection modalities: a randomized prospective clinical trial. *Journal of the American Podiatric Medical Association*, 99(2), 108-113.
- Kim, C., Cashdollar, M. R., Mendicino, R. W., Catanzariti, A. R., & Fuge, L. (2010). Incidence of plantar fascia ruptures following corticosteroid injection. *Foot & Ankle Specialist*, *3*(6), 335-337. doi:http://dx.doi.org/10.1177/1938640010378530
- Kirkland, P., & Beeson, P. (2013). Use of primary corticosteroid injection in the management of plantar fasciopathy: Is it time to challenge existing practice? *Journal of the American Podiatric Medical Association*, 103(5), 418-429.
- Kiter, E., Çelikbas, E., Akkaya, S., & Demirkan, F. (2006). Comparison of injection modalities in the treatment of plantar heel pain: a randomized controlled trial. *Journal of the American Podiatric Medical Association*, *96*(4), 293-296.
- Lafuente Guijosa, A., O'Mullony Munoz, I., de La Fuente, M. E., & Cura-Ituarte, P. (2007). [Plantar fascitis: evidence-based review of treatment]. *Reumatologia Clinica*, *3*(4), 159-165. doi:http://dx.doi.org/10.1016/S1699-258X(07)73614-8
- Lee, H., Choi, Y., Kim, S., Lee, J., Seo, J., & Jeong, J. (2014). Risk factors affecting chronic rupture of the plantar fascia. *Foot and Ankle International*, *35*(3), 258-263.
- Lee, T. G., & Ahmad, T. S. (2007). Intralesional autologous blood injection compared to corticosteroid injection for treatment of chronic plantar fasciitis. A prospective, randomized, controlled trial. *Foot and Ankle International*, *28*(9), 984-990. doi:http://dx.doi.org/10.3113/FAI.2007.0984
- Li, S., Shen, T., Liang, Y., Zhang, Y., & Bai, B. (2014). Miniscalpel-needle versus steroid injection for plantar fasciitis: A randomized controlled trial with a 12-month follow-up. *Evidence-based Complementary and Alternative Medicine*, 2014. doi:10.1155/2014/164714
- Li, Z., Yu, A., Qi, B., Zhao, Y., Wang, W., Li, P., & Ding, J. (2015). Corticosteroid versus placebo injection for plantar fasciitis: A meta-analysis of randomized controlled trials. *Experimental and Therapeutic Medicine*, *9*(6), 2263-2268. doi:http://dx.doi.org/10.3892/etm.2015.2384
- Lim, A. T., How, C. H., & Tan, B. (2016). Management of plantar fasciitis in the outpatient setting. *Singapore Medical Journal*, *57*(4), 168.
- Mahindra, P., Yamin, M., Selhi, H. S., Singla, S., & Soni, A. (2016). Chronic plantar fasciitis: Effect of platelet- rich plasma, corticosteroid, and placebo. *Orthopedics*, *39*(2), e285-e289. doi:http://dx.doi.org/10.3928/01477447-20160222-01
- Mardani-Kivi, M., Karimi, M. M., Hassanzadeh, Z., Mirbolook, A., Asadi, K., Ettehad, H., . . . Fallah-Alipour, K. (2015). Treatment Outcomes of Corticosteroid Injection and Extracorporeal Shock Wave Therapy as Two Primary Therapeutic Methods for Acute Plantar Fasciitis: A Prospective Randomized Clinical Trial. *The Journal of foot and ankle surgery: official publication of the American College of Foot and Ankle Surgeons, 54*(6), 1047-1052. doi:10.1053/j.jfas.2015.04.026



- McMillan, A. M., Landorf, K. B., Gilheany, M. F., Bird, A. R., Morrow, A. D., & Menz, H. B. (2012). Ultrasound guided corticosteroid injection for plantar fasciitis: randomised controlled trial. *BMJ*, *344*, e3260. doi:http://dx.doi.org/10.1136/bmj.e3260
- Monto, R. R. (2014). Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis. *Foot and Ankle International, 35*(4), 313-318. doi:http://dx.doi.org/10.1177/1071100713519778
- Motififard, M., Javdan, M., & Teimouri, M. (2008). Comparative study of the therapeutic effects of corticosteroid injection accompanied by casting and heel pad in treatment of heel pain. *Journal of Research in Medical Sciences*, *13*(4), 175-180.
- Mulherin, D., & Price, M. (2009). Efficacy of tibial nerve block, local steroid injection or both in the treatment of plantar heel pain syndrome. *Foot,* 19(2), 98-100. doi:http://dx.doi.org/10.1016/j.foot.2009.01.003
- Narula, R., Iraqi, A. A., Narula, K., Katyal, R., & Saxena, M. S. (2014). Comparative Study of: Non-Invasive Conservative Treatments with Local Steroid Injection in the Management of Planter Fasciitis. *Journal of Clinical and Diagnostic Research JCDR*, 8(9), LC05-07. doi:http://dx.doi.org/10.7860/JCDR/2014/10354.4895
- Omar, A., Ibrahim, M., Ahmed, A., & Said, M. (2012). Local injection of autologous platelet rich plasma and corticosteroid in treatment of lateral epicondylitis and plantar fasciitis: Randomized clinical trial. *Egyptian Rheumatologist*, 34(2), 43-49. doi:10.1016/j.ejr.2011.12.001
- Porter, M. D., & Shadbolt, B. (2005). Intralesional corticosteroid injection versus extracorporeal shock wave therapy for plantar fasciopathy. *Clinical Journal of Sport Medicine*, 15(3), 119-124.
- Ryan, M., Hartwell, J., Fraser, S., Newsham-West, R., & Taunton, J. (2014). Comparison of a physiotherapy program versus dexamethasone injections for plantar fasciopathy in prolonged standing workers: a randomized clinical trial. *Clinical Journal of Sport Medicine*, 24(3), 211-217. doi:http://dx.doi.org/10.1097/JSM.00000000000000021
- Saba, E., & El-Sherif, S. (2016). Ultrasound-guided versus palpation-guided local corticosteroid injection therapy for treatment of plantar fasciitis. *Egyptian Rheumatologist*, *38*(2), 123-131. doi:10.1016/j.ejr.2015.06.005
- Snow, D. M., Reading, J., & Dalal, R. (2005). Lateral plantar nerve injury following steroid injection for plantar fasciitis. *British Journal of Sports Medicine*, 39(12), e41; discussion e41.
- Speed, C. A. (2007). Injection therapies for soft-tissue lesions. *Best Practice & Research Clinical Rheumatology*, *21*(2), 333-347.
- Tatli, Y. Z., & Kapasi, S. (2009). The real risks of steroid injection for plantar fasciitis, with a review of conservative therapies. *Current reviews in musculoskeletal medicine*, *2*(1), 3-9. doi:http://dx.doi.org/10.1007/s12178-008-9036-1



- Tiwari, M., & Bhargava, R. (2013). Platelet rich plasma therapy: A comparative effective therapy with promising results in plantar fasciitis. *Journal of Clinical Orthopaedics and Trauma, 4*(1), 31-35. doi:http://dx.doi.org/10.1016/j.jcot.2013.01.008
- Tsai, W., Wang, C., Tang, F., Hsu, T., Hsu, K., & Wong, M. (2000). Treatment of proximal plantar fasciitis with ultrasound-guided steroid injection. *Archives of Physical Medicine and Rehabilitation*, 81(10), 1416-1421.
- Tsai, W. C., Hsu, C. C., Chen, C. P., Chen, M. J., Yu, T. Y., & Chen, Y. J. (2006). Plantar fasciitis treated with local steroid injection: comparison between sonographic and palpation guidance. *Journal of Clinical Ultrasound*, *34*(1), 12-16.
- Tsikopoulos, K., Tsikopoulos, A., & Natsis, K. (2016). Autologous whole blood or corticosteroid injections for the treatment of epicondylopathy and plantar fasciopathy? A systematic review and meta-analysis of randomized controlled trials. *Physical Therapy in Sport.*, 10. doi:http://dx.doi.org/10.1016/j.ptsp.2016.02.002
- Uden, H., Boesch, E., & Kumar, S. (2011). Plantar fasciitis to jab or to support? A systematic review of the current best evidence. *Journal of Multidisciplinary Healthcare, 4*, 155-164. doi:10.2147/JMDH.S20053
- Wong, M. W. N., Tang, Y. N., Fu, S. C., Lee, K. M., & Chan, K. M. (2004). Triamcinolone suppresses human tenocyte cellular activity and collagen synthesis. *Clinical Orthopaedics and Related Research*, 421, 277-281.
- Yesiltas, F., Aydogan, U., Parlak, A., Sari, O., Akgun, V., Kurklu, M., . . . Sagla, M. (2015). The comparison of intralesionary steroid injection and autologous venous blood injection in patients with plantar fasciitis. *31*(3), 711-716.
- Yucel, I., Ozturan, K. E., Demiraran, Y., Degirmenci, E., & Kaynak, G. (2010). Comparison of high-dose extracorporeal shockwave therapy and Intralesional corticosteroid injection in the treatment of plantar fasciitis. *Journal of the American Podiatric Medical Association*, 100(2), 105-110.
- Yucel, I., Yazici, B., Degirmenci, E., Erdogmus, B., & Dogan, S. (2009). Comparison of ultrasound, palpation-, and scintigraphy-guided steroid injections in the treatment of plantar fasciitis. *Archives of Orthopaedic & Trauma Surgery, 129*(5), 695-701. doi:http://dx.doi.org/10.1007/s00402-008-0760-1
- Yucel, U., Kucuksen, S., Cingoz, H., Anliacik, E., Ozbek, O., Salli, A., & Ugurlu, H. (2013). Full-length silicone insoles versus ultrasound-guided corticosteroid injection in the management of plantar fasciitis: a randomized clinical trial. *Prosthetics and Orthotics International*, *37*(6), 471-476.



# 6. Appendices

#### Appendix 1: Search string used in Medline

Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present>

#### Search Strategy:

- 1 Betamethasone/
- 2 Dexamethasone/
- 3 Fluocortolone/
- 4 Methylprednisolone/
- 5 Paramethasone/
- 6 Prednisolone/
- 7 Prednisone/
- 8 Triamcinolone/
- 9 Hydrocortisone/
- 10 Cortisone/
- 11 Methandrostenolone/
- 12 Stanozolol/
- 13 Methenolone/
- 14 Oxymetholone/
- 15 Oxandrolone/
- 16 Nandrolone/
- 17 exp Steroids/
- 18 steroid\$1.ti,ab.
- 19 (betamethasone or dexamethasone or fluocortolone or methylprednisolone or paramethasone or prednisolone or prednisone or triamcinolone or hydrocortisone or cortisone or prednylidene or rimexolone or deflazacort or cloprednol or meprednisone or cortivazol).ti,ab.
- 20 (androstanolone or stanozolol or metandienone or metenolone or oxymetholone or quinbolone or prasterone or oxandrolone or norethandrolone).ti,ab.
- 21 (nandrolone or ethylestrenol or oxabolone cipionate).ti,ab.
- 22 (Diflucortolone or Fluprednisolone or Methylprednisolone or Prednimustine or Methandrostenolone).ti,ab.
- 23 or/1-22
- 24 Injections/
- 25 injection\*.ti,ab.
- 26 or/24-25
- 27 exp Pain/
- 28 pain.ti,ab.
- 29 or/27-28
- 30 Heel/
- 31 Fasciitis, Plantar/
- 32 Fasciitis/
- 33 (heel or plantar fasciitis or heel spur or plantar aponeurosis).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 34 or/30-33
- 35 and/23,26,29,34



#### Appendix 2: Critical appraisal tools used within this review

#### SIGN Critical Appraisal Tool for systematic reviews and Meta-analyses



# Methodology Checklist 1: systematic reviews and Metaanalyses

SIGN gratefully acknowledges the permission received from the authors of the AMSTAR tool to base this checklist on their work: Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C,. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007, 7:10 doi:10.1186/1471-2288-7-10. Available from <a href="http://www.biomedcentral.com/1471-2288/7/10">http://www.biomedcentral.com/1471-2288/7/10</a> [cited 10 Sep 2012]

| Study i         | identification (Include author, title, year of publication  | , journal title, pages)           |                     |  |  |
|-----------------|---|-----------------------------------|---------------------|--|--|
|                 |   |                                   |                     |  |  |
| Guidel          | ine topic:  | Key Question No:                  | / Question No:      |  |  |
| Before          | completing this checklist, consider:  |                                   |                     |  |  |
| Is the<br>Compa | paper relevant to key question? Analyse using PICo<br>arison Outcome). IF NO reject. IF YES complete the c  | O (Patient or Populati hecklist.  | on Intervention     |  |  |
| Check           | list completed by:  |                                   |                     |  |  |
| Sectio          | n 1: Internal validity  |                                   |                     |  |  |
| In a w          | vell conducted systematic review:   | Does this study                   | y do it?            |  |  |
| 1.1             | The research question is clearly defined and the inclusion/ exclusion criteria must be listed in the paper. | Yes □ If no reject                | No 🗆                |  |  |
| 1.2             | A comprehensive literature search is carried out.   | Yes  Not applicable  If no reject | No 🗆                |  |  |
| 1.3             | At least two people should have selected studies.   | Yes 🗆                             | No □<br>Can't say □ |  |  |
| 1.4             | At least two people should have extracted data.   | Yes 🗆                             | No □<br>Can't say □ |  |  |
| 1.5             | The status of publication was not used as an inclusion criterion.   | Yes 🗆                             | No 🗆                |  |  |
| 1.6             | The excluded studies are listed.  | Yes □                             | No □                |  |  |
| 1.7             | The relevant characteristics of the included studies are provided.  | Yes 🗆                             | No 🗆                |  |  |
| 1.8             | The scientific quality of the included studies was assessed and reported.                                   | Yes 🗆                             | No 🗆                |  |  |
| 1.9             | Was the scientific quality of the included studies use appropriately?                                       | ed Yes 🗆                          | No □                |  |  |



| 1.10  | Appropriate methods are used to combine the individual study findings.                             | Yes □<br>Can't say □ | No   Not applicable |  |  |  |  |
|-------|--|----------------------|---------------------|--|--|--|--|
| 1.11  | The likelihood of publication bias was assessed appropriately.                                     | Yes   Not applicable | No 🗆                |  |  |  |  |
| 1.12  | Conflicts of interest are declared.  | Yes □                | No □                |  |  |  |  |
| SECTI | SECTION 2: OVERALL ASSESSMENT OF THE STUDY   |                      |                     |  |  |  |  |
| 2.1   | What is your overall assessment of the methodological quality of this review?                      | High quality (++)    |                     |  |  |  |  |
|       |  | Unacceptable – re    | eject u 🗆           |  |  |  |  |
| 2.2   | Are the results of this study directly applicable to the patient group targeted by this guideline? | Yes                  | No □                |  |  |  |  |



### **SIGN Critical Appraisal Tool for Controlled trials**

| SIG              | Methodology Checklist 2: Contro  | olle                | d Trials             |                           |    |
|------------------|--|---------------------|----------------------|---------------------------|----|
| Study            | dentification (Include author, title, year of publication, journal t   | title, <sub>l</sub> | pages)               |                           |    |
| Guidel           | ine topic:   | Key                 | Question No:         | Rev<br>wer                |    |
| Before           | completing this checklist, consider:   |                     |                      |                           |    |
| 1.               | Is the paper a randomised controlled trial or a controlled check the study design algorithm available from SIGN and m checklist. If it is a controlled clinical trial questions 1.2, 1.3, the study cannot be rated higher than 1+ | nake s              | sure you have        | the corre                 |    |
| 2.               | Is the paper relevant to key question? Analyse using PICO (Fintervention Comparison Outcome). IF NO REJECT (give reathe checklist.   |                     |                      |                           | te |
| Reaso<br>specify | n for rejection: 1. Paper not relevant to key question □ 2. Oth<br>'):   | ner re              | ason 🗆 (pleas        | se                        |    |
| SECTI            | ON 1: INTERNAL VALIDITY  |                     |                      |                           |    |
| In a w           | ell conducted RCT study  |                     | Does this stu        | dy do it:                 | ?  |
| 1.1              | The study addresses an appropriate and clearly focused question.   |                     | Yes □<br>Can't say □ | No □                      |    |
| 1.2              | The assignment of subjects to treatment groups is randomise  |                     | Yes □<br>Can't say □ | No □                      |    |
| 1.3              | An adequate concealment method is used.  |                     | Yes □<br>Can't say □ | No □                      |    |
| 1.4              | The design keeps subjects and investigators 'blind' about treatment allocation.  |                     | Yes □<br>Can't say □ | No □                      |    |
| 1.5              | The treatment and control groups are similar at the start of th trial.   |                     | Yes □<br>Can't say □ | No □                      |    |
| 1.6              | The only difference between groups is the treatment under investigation.   |                     | Yes □<br>Can't say □ | No □                      |    |
| 1.7              | All relevant outcomes are measured in a standard, valid and reliable way.  |                     | Yes □<br>Can't say □ | No □                      |    |
| 1.8              | What percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?  | у                   |                      |                           |    |
| 1.9              | All the subjects are analysed in the groups to which they were randomly allocated (often referred to as intention to treat analysis).  | C                   | Yes □<br>Can't say □ | No □<br>Does n<br>apply □ |    |



| 1.10 | Where the study is carried out at more than one site, re are comparable for all sites.  | esults              | Yes □<br>Can't say □ | No □<br>Does not<br>apply □ |
|------|---|---------------------|----------------------|-----------------------------|
| SECT | ION 2: OVERALL ASSESSMENT OF THE STUDY  |                     |                      |                             |
| 2.1  | How well was the study done to minimise bias? Code as follows:  | Acceptal<br>Low qua |                      |                             |
| 2.2  | Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, are you certain that the overall effect is due to the study intervention? |                     |                      |                             |
| 2.3  | Are the results of this study directly applicable to the patient group targeted by this guideline?  |                     |                      |                             |
| 2.4  | <b>Notes.</b> Summarise the authors' conclusions. Add any of the study, and the extent to which it answers your quencertainty raised above.   |                     | •                    |                             |



### **SIGN Critical Appraisal Tool for case-control studies**

| SIGN     | Methodology Checklist 3: case-control st  | tudies                 |                          |
|----------|---|------------------------|--------------------------|
| 0101     |   |                        |                          |
| Study i  | dentification (Include author, title, year of publication, jou  | urnal title, page      | es)                      |
| Guideli  | ne topic:   | Key<br>Question<br>No: | Reviewer:                |
| Before ( | completing this checklist, consider:  |                        |                          |
| 1.       | Is the paper really a case-control study? If in doubt, check available from SIGN and make sure you have the correct     |                        | gn algorithm             |
| 2.       | Is the paper relevant to key question? Analyse using PICC Intervention Comparison Outcome). IF NO REECT (give checklist |                        |                          |
| Reason   | for rejection: 1. Paper not relevant to key question □ 2.   | Other reason [         | ] (please specify):      |
|          | note that a retrospective study (ie a database or chart study   |                        |                          |
| Secti    | on 1: Internal validity   |                        |                          |
| In a we  | ell conducted cohort study:   | Does this s            | study do it?             |
| 1.1      | The study addresses an appropriate and clearly focused question.  | Yes □<br>Can't say □   | No 🗆                     |
| SELEC    | CTION OF SUBJECTS   |                        |                          |
| 1.2      | The cases and controls are taken from comparable populations.   | Yes □<br>Can't say □   | No □<br>Does not apply □ |
| 1.3      | The same exclusion criteria are used for both cases and controls.   | Yes 🗆                  | No □<br>Does not apply □ |
| 1.4      | What percentage of each group (cases and controls) participated in the study?   | Yes □<br>Can't say □   | No □<br>Does not apply □ |
| 1.5      | Comparison is made between participants and non-<br>participants to establish their similarities or<br>differences.     | Yes □<br>Can't say □   | No □<br>Does not apply □ |
| 1.6      | Cases are clearly defined and differentiated from controls.   | Yes □<br>Can't say □   | No □<br>Does not apply □ |
| 1.7      | The outcomes are clearly defined.   | Yes □<br>Can't say □   | No 🗆                     |



| ASSE  | SSMENT  |                |              |        |
|-------|---|----------------|--------------|--------|
| 1.8   | Measures will have been taken to prevent knowledge  | Yes □          | No □         |        |
|       | of primary exposure influencing case ascertainment.   | Can't say □    | Does not ap  | oply 🗆 |
|       |   |                |              |        |
| 1.9   | Exposure status is measured in a standard, valid and  | Yes □          | No □         |        |
|       | reliable way  | Can't say □    |              |        |
| CONF  | OUNDING   |                |              |        |
| 1.10  | The main potential confounders are identified and   | Yes □          | No □         |        |
|       | taken into account in the design and analysis.  | Can't say □    |              |        |
| STATI | STICAL ANALYSIS   |                |              |        |
| 1.14  | Confidence intervals are provided   | Yes □          | No □         |        |
| SECT  | ON 2: OVERALL ASSESSMENT OF THE STUDY   | 1              |              |        |
| 2.1   | How well was the study done to minimise the risk of   | High quality ( | ++) 🗆        |        |
|       | bias or confounding?  | Acceptable (-  |              |        |
|       |   | Unacceptable   | e – reject 0 |        |
| 2.2   | Taking into account clinical considerations, your   | Yes □          |              | No □   |
|       | evaluation of the methodology used, and the   | Can't say □    |              |        |
|       | statistical power of the study, do you think there is clear evidence of an association between exposure |                |              |        |
|       | and outcome?  |                |              |        |
| 2.3   | And the meanite of this office directly applied by the  | Yes 🗆          |              | No □   |
|       | Are the results of this study directly applicable to the  | . 00 🗅         |              | I VO   |
|       | patient group targeted in this guideline?   | 100 🛮          |              | 140 🗆  |
| 2.4   | patient group targeted in this guideline?  Notes. Summarise the authors conclusions. Add any c          | omments on ye  |              |        |
| 2.4   | patient group targeted in this guideline?   | omments on ye  |              |        |



Appendix 3: Quality scores for articles used in this review (systematic reviews)

| Reference (author | , year) | Quest |     |     |     |     |     |     |     |     |      |      |      |         |
|-------------------|---------|-------|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|---------|
| Study             | Year    | 1.1   | 1.2 | 1.3 | 1.4 | 1.5 | 1.6 | 1.7 | 1.8 | 1.9 | 1.10 | 1.11 | 1.12 | 2.1     |
| Ang               | 2015    | Υ     | Υ   | CS  | CS  | N   | N   | Υ   | Υ   | Υ   | NA   | N    | N    | LQ (-)  |
| Atkins et al      | 1999    | Υ     | Υ   | CS  | Υ   | Υ   | N   | Υ   | Υ   | Υ   | NA   | N    | Υ    | AQ (+)  |
| Crawford et al    | 2002    | Υ     | Υ   | Υ   | Υ   | Υ   | Υ   | Υ   | Υ   | Υ   | NA   | N    | Υ    | HQ (++) |
| Crawford et al    | 2003    | Υ     | Υ   | Υ   | Υ   | Υ   | Υ   | Υ   | Υ   | Υ   | NA   | N    | Υ    | HQ (++) |
| Lafuente et al    | 2007    | Υ     | Υ   | CS  | CS  | N   | N   | N   | N   | N   | NA   | N    | N    | LQ (-)  |
| Li et al          | 2015    | Υ     | Υ   | Υ   | CS  | N   | N   | Υ   | Υ   | Υ   | Υ    | N    | Ν    | AQ (+)  |
| Tatli et al       | 2009    | Υ     | N   | CS  | CS  | N   | N   | N   | N   | N   | NA   | N    | Ν    | LQ (-)  |
| Tsikopoulos et al | 2016    | Υ     | Υ   | Υ   | Υ   | Υ   | N   | Υ   | Υ   | Υ   | Υ    | N    | Υ    | HQ (++) |
| Uden et al        | 2011    | Υ     | Υ   | Υ   | Υ   | Ν   | Υ   | -   | Υ   | Υ   | NA   | Ν    | Υ    | HQ (++) |



Appendix 4: RCTs included in SRs

|                               |                     | Systematic Reviews    Lafuente et al., 2007 |   |                  |                       |                      |                          |                 |                   |                       |       |  |  |  |  |
|-------------------------------|---------------------|---|---|------------------|-----------------------|----------------------|--------------------------|-----------------|-------------------|-----------------------|-------|--|--|--|--|
|                               | Atkins et al., 1999 | Crawford et al. 2002                        |   | Tatli et al 2009 | Lafuente et al., 2007 | Crawford et al. 2003 | Tsikopoulos et al., 2016 | Ang et al, 2015 | Uden et al., 2011 | Lafuente et al., 2007 | Total |  |  |  |  |
| RCTs                          |                     |   |   |                  |                       |                      |                          |                 |                   |                       |       |  |  |  |  |
| Crawford 1999                 |                     |   | 1 | 1                | 1                     | 1                    |                          | 1               |                   | 1                     | 6     |  |  |  |  |
| McMillan et al 2012           |                     |   | 1 |                  |                       |                      |                          | 1               |                   |                       | 2     |  |  |  |  |
| Abdihakin 2012                |                     |   | 1 |                  |                       |                      |                          |                 |                   |                       | 1     |  |  |  |  |
| Ball et al 2013               |                     |   | 1 |                  |                       |                      |                          | 1               |                   |                       | 2     |  |  |  |  |
| Black et al 1996              | 1                   | 1   |   |                  |                       | 1                    |                          |                 |                   | 1                     | 4     |  |  |  |  |
| Blockey 1956                  | 1                   |   |   |                  |                       | 1                    |                          |                 |                   |                       | 2     |  |  |  |  |
| Kriss 1990                    | 1                   | 1   |   |                  |                       | 1                    |                          |                 |                   | 1                     | 4     |  |  |  |  |
| Lynch et al 1998              |                     |   |   |                  |                       | 1                    |                          |                 |                   | 1                     | 2     |  |  |  |  |
| Lee et al 2007                |                     |   |   |                  |                       |                      | 1                        | 1               |                   |                       | 2     |  |  |  |  |
| Kiter et al 2006              |                     |   |   |                  |                       |                      | 1                        | 1               |                   |                       | 2     |  |  |  |  |
| Kalaci 2009                   |                     |   |   |                  |                       |                      | 1                        |                 |                   |                       | 1     |  |  |  |  |
| Ryan et al 2014               |                     |   |   |                  |                       |                      |                          | 1               |                   |                       | 1     |  |  |  |  |
| Guner et al 2013              |                     |   |   |                  |                       |                      |                          | 1               |                   |                       | 1     |  |  |  |  |
| Yucel et al 2013              |                     |   |   |                  |                       |                      |                          | 1               |                   |                       | 1     |  |  |  |  |
| Elizondo-Rodriguez et al 2013 |                     |   |   |                  |                       |                      |                          | 1               |                   |                       | 1     |  |  |  |  |
| Diaz-Liopis et al 2012        |                     |   |   |                  |                       |                      |                          | 1               |                   |                       | 1     |  |  |  |  |
| Porter and Shadbolt 2005      |                     |   |   |                  |                       |                      |                          |                 | 1                 |                       | 1     |  |  |  |  |
| Lee and Ahmad 2007            |                     |   |   |                  |                       |                      |                          |                 | 1                 |                       | 1     |  |  |  |  |
|                               |                     |   |   |                  |                       |                      |                          |                 |                   |                       |       |  |  |  |  |
| Total                         | 3                   | 2   | 4 | 1                | 1                     | 5                    | 3                        | 10              | 2                 | 4                     |       |  |  |  |  |

# Appendix 5: Quality scores for articles used in this review (RCTs)

| Reference (author | , year)   |   |          |           |          |                     |                    | Qı                    | ıest                  |          |           |  |          |        |
|-------------------|---|---|----------|-----------|----------|---------------------|--------------------|-----------------------|-----------------------|----------|-----------|--|----------|--------|
| Study             | Year  | 1.1   | 1.2      | 1.3       | 1.4      | 1.5                 | 1.6                | 1.7                   | 1.8                   | 1.9      | 1.10      | 2.1  | 2.2      | 2.3    |
| Ahmed et al       | 2013  | Υ   | CS       | N         | N        | Υ                   | Υ                  | Υ                     | 0%                    | NA       | NA        | LQ (-)   | N        | Υ      |
| 2.4               | Local   | methy   | lpredni  | solone i  | -        |                     |                    |                       | exametha              |          | -         | , in providing   | short t  | erm    |
| Al-Bluwi et al    | 2011  | Υ   | CS       | N         | CS       | N                   | CS                 | Υ                     | 0.5%                  | CS       | NA        | LQ (-)   | N        | N      |
| 2.4               | For bo  | th pain   | VAS ar   | nd SFMI   |          | -                   |                    | _                     | ficantly le           |          | ective th | an EZStep ort  | hotic d  | evice  |
| Biswas et al      | 2011  | Υ   | N        | N         | CS       | Υ                   | N                  | N                     | CS                    | CS       | NA        | LQ (-)   | N        | Υ      |
| 2.4               | Ĺ   | ocal in   | jection  | of stere  | oid is m | ore effe            | ective ir          | the tre               | atment c              | of plant | ar fascii | tis than oral N  | ISAIDs   |        |
| Canyilmaz et al   | 2015  | Υ   | N        | N         | N        | N                   | N                  | Υ                     | 3.1%                  | Υ        | NA        | LQ (-)   | N        | Υ      |
| 2.4               | Radi  | ation tl  | nerapy i | is more   | effectiv | e at re             |                    | oain tha<br>fasciitis |                       | on-gui   | ded ster  | oid injection f  | or plan  | ntar   |
| Celik et al       | 2016  | Υ   | Υ        | Υ         | Υ        | Υ                   | N_                 | Υ                     | 9.3%                  | Υ        | NA        | HQ (++)  | Υ        | Υ      |
| 2.4               | injecti   | on gro  | up dem   | onstrat   | ed bett  | er outc             | omes a<br>a period | t all 3 ti            | me point<br>e ranging | s. Impr  | ovemen    | follow-ups, the sustants of th | ined fo  | r the  |
| Chen et al        |   |   |          |           |          |                     |                    |                       |                       |          |           |  | N        | Υ      |
| 2.4               | Dev   | Device-assisted ultrasound-guided injection for treating plantar fasciitis results in better therapeutic outcomes than palpation-guided injection |          |           |          |                     |                    |                       |                       |          |           |  |          |        |
| Eslamian et al    | 2016  | Υ   | Υ        | CS        | Υ        | Υ                   | Υ                  | Υ                     | 0%                    | Υ        | NA        | HQ (++)  | Υ        | Υ      |
| 2.4               | inter   | -group  | differe  | nces we   | ere not  | signific<br>thus sh | ant, foo<br>ockwav | t functi<br>e thera   | on was in             | nprove   | d more    | after treatmer<br>with ESWT an<br>tive for manag   | d patie  | ents   |
| Hanselman et al   | 2015  | Υ   | CS       | N         | Υ        | CS                  | Υ                  | Υ                     | 4.2%                  | N        | NA        | LQ (-)   | N        | Υ      |
| 2.4               | Cry   | -   |          |           |          |                     | -                  |                       | -                     |          | -         | rable to cortic<br>r investigation   |          | d      |
| Jain et al        | 2015  | Υ   | CS       | N         | N        | Υ                   | Υ                  | Υ                     | CS                    | CS       | NA        | LQ (-)   | N        | Υ      |
| 2.4               | treatm  | ent of <sub>l</sub>   | olantar  | fasciitis | , but ur | nlike ste           | eroid, it          | s effect              | does not              | wear c   | off with  | iths after injec<br>time. At 12 m<br>nan cortisone   | onths, I | PRP is |
| Li et al          | 2014  | Υ   | Υ        | Υ         | CS       | Υ                   | Υ                  | Υ                     | 11.5%                 | Υ        | NA        | HQ (++)  | Υ        | Υ      |
| 2.4               |   | Miniso  |          |           |          |                     |                    |                       |                       |          |           | ction in treati  | ng PF    |        |
| Mahindra et al    | 2016  | Y   | Υ        | Y         | Y        | Υ                   | Υ                  | Υ                     | CS                    | Υ        | NA        | HQ (++)  | Y        | Υ      |
| 2.4               | Local injection of platelet-rich plasma or corticosteroid is an effective treatment option for chronic PF.  Platelet-rich plasma injection is as effective as corticosteroid injection in treating chronic PF |   |          |           |          |                     |                    |                       |                       |          | PF.       |  |          |        |
| Mardani-Kivi      | 2015  | Υ   | Υ        | CS        | Υ        | Υ                   | Υ                  | Υ                     | 19.0%                 | N        | NA        | AQ (+)   | Υ        | Υ      |
| 2.4               | Both  | ESWT a  | and ster | -         |          |                     |                    |                       | eatment of injection  | •        |           | ating patients<br>ve   | with a   | cute   |
| McMillan et al    | 2012  | Υ   | Υ        | Υ         | Υ        | Υ                   | Υ                  | Υ                     | 1.2%                  | Υ        | NA        | HQ (++)  | Υ        | Υ      |
| 3.4               | _   |   | -        | _         |          |                     | -                  |                       |                       |          |           | term treatme   |          |        |
| 2.4               | provid  | _   | -        |           | -        |                     |                    |                       |                       |          |           | welling of the<br>nd four weeks  |          | ap to  |



| Reference (author    | , year)  |          |           |           |          |          |          | Qı       | uest                     |          |           |                                       |          |        |
|----------------------|--|----------|-----------|-----------|----------|----------|----------|----------|--------------------------|----------|-----------|---------------------------------------|----------|--------|
| Study                | Year   | 1.1      | 1.2       | 1.3       | 1.4      | 1.5      | 1.6      | 1.7      | 1.8                      | 1.9      | 1.10      | 2.1                                   | 2.2      | 2.3    |
| 2.4                  | Platel   | et-rich  | plasma    | injecti   | on was   |          |          |          | urable tha<br>t cases of |          | oid injec | tion for the tr                       | eatmer   | nt of  |
| Motififard et al     | 2008   | Υ        | CS        | N         | N        | CS       | N        | N        | CS                       | CS       | CS        | Reject (0)                            | N        | N      |
| 2.4                  | Cortico  | steroid  | linjectio | n toge    | ther wi  | th casti | ng was   | more e   | ffective a               | t treati | ng heel   | pain than use                         | of hee   | l pads |
| Mulherin & Price     | 2009   | Υ        | CS        | N         | CS       | CS       | CS       | Υ        | CS                       | CS       | NA        | Reject (0)                            | N        | N      |
| 2.4                  |  | _        | discomf   | ort of th | ne proc  | edure,   | that a s | teroid i |                          | o the h  | neel may  | ome, a tibial i<br>accelerate in      |          |        |
| Narula et al         | 2014   | Υ        | CS        | N         | N        | CS       | N        | Υ        | 27.5%                    | N        | NA        | Reject (0)                            | N        | N      |
| 2.4                  | As bo  | oth trea |           |           |          | •        |          |          | nent outo                | -        |           | er to go for co                       | nserva   | tive   |
| Omar et al           | 2012   | Υ        | CS        | N         | N        | Υ        | Υ        | Υ        | CS                       | CS       | NA        | Reject (0)                            | N        | N      |
| 2.4                  |  | PRP      | was mo    | re effe   | ctive th | an ster  | oid inje | ction in | relieving                | the sh   | ort-term  | symptoms o                            | f PF     |        |
| Saba & El-Sherif     | 2015   | Υ        | CS        | N         | N        | Υ        | Υ        | Υ        | 0%                       | Υ        | NA        | LQ (-)                                | N        | Υ      |
| 2.4                  |  |          |           | oth tec   | hnique   | s impro  | ved PF   | clinical |                          | rasono   | graphica  | fective and sually without st<br>tion |          |        |
| Tiwari &<br>Bhargava | 2013   | Υ        | CS        | N         | N        | CS       | Υ        | N        | cs                       | CS       | NA        | Reject (0)                            | N        | N      |
| 2.4                  |  |          | PRP in    | jection   | is more  | e effect | ive thar | steroi   | d injection              | at rel   | ieving p  | ain from PF                           |          |        |
| Tsai et al           | 2006   | Υ        | CS        | N         | N        | Υ        | Υ        | Υ        | 0%                       | CS       | NA        | LQ (-)                                | N        | Υ      |
| 2.4                  | St   | eroid i  | njection  | can be    |          |          | -        |          | and injections           |          |           | nographic guid                        | dance is | ;      |
| Yesiltas et al       | 2015   | Υ        | Υ         | Υ         | N        | N        | Υ        | N        | 22.4%                    | CS       | NA        | LQ (-)                                | N        | Υ      |
| 2.4                  | Intralesional steroid injection and autologous venous blood injection have comparable effectiveness in treatment of PF |          |           |           |          |          |          |          |                          |          | n the     |                                       |          |        |
| Yucel et al          | 2010   | Υ        | CS        | N         | N        | N        | Υ        | Υ        | 0%                       | CS       | NA        | LQ (-)                                | N        | Υ      |
| 2.4                  | 2.4 Corticosteroid injection and ESWT are comparable in effectiveness in treating the symptoms of chror                |          |           |           |          |          |          |          |                          |          |           | f chron                               | ic PF    |        |
| Yucel et al          | 2009   | Υ        | CS        | N         | N        | N        | Υ        | Υ        | CS                       | CS       | NA        | LQ (-)                                | N        | Υ      |
| 2.4                  | -  | -        |           | _         |          | ence b   | etween   | these t  |                          | s in tei |           | plantar fasciit<br>Iantar fascia t    |          |        |



### Appendix 6: Quality scores for articles used in this review (case-control studies)

| Reference (autho | r, year) |  |     |     |     |     |     |     |     |     |      |     |     |     |  |
|------------------|----------|--|-----|-----|-----|-----|-----|-----|-----|-----|------|-----|-----|-----|--|
| Study            | Year     | 1.1  | 1.2 | 1.3 | 1.4 | 1.5 | 1.6 | 1.7 | 1.8 | 1.9 | 1.10 | 2.1 | 2.2 | 2.3 |  |
| Lee et al        | 2014     | 2014 Y Y CS CS Y Y Y DNA CS Y AQ (+) Y   |     |     |     |     |     |     |     |     |      |     | Υ   |     |  |
| 2.4              | Stero    | Steroid injections for plantar fasciitis should be cautiously administered because of the higher risk for plantar fascia rupture |     |     |     |     |     |     |     |     |      |     |     |     |  |



### Appendix 7: Extracted data from included systematic reviews

| Author and              | SIGN    | Approach   | Studies            | Outcome  | Conclusions  | E, | vide | ence | 9 | Grade |
|-------------------------|---------|--|--------------------|--|--|----|------|------|---|-------|
| year                    | Score   |  | (patient No)       |  |  | 1  | 2    | 3    | 4 | Grade |
|                         |         | Various corticosteroids<br>(dexamethasone,<br>betamethasone,<br>methylprednisolone,<br>prednisolone, | 10 RCTs; N =       | Foot or heel pain, heel  | <ul> <li>Two high-quality RCTs demonstrated strong evidence of effectiveness for heel pain and plantar fascia thickness, lasting for up to three months for patients that had failed two months of conservative treatment.</li> <li>There was no difference in effectiveness between ultrasound and palpation-guided injections or choice of corticosteroid injection</li> </ul>   |    |      |      |   |       |
| Ang, 2015               | LQ (-)  | triamcinolone), approaches (medial, posterior, heel pad), and guidance (palpation and ultrasound)    | 622                | tenderness, plantar<br>fascia thickness  | <ul> <li>In comparison to other treatment modalities, corticosteroid injection was similar in effectiveness to physiotherapist-led exercise, more effective than use of silicone insoles, less effective than injection with botulinum toxin A, and more effective than injection with autologous blood.</li> </ul>  | 0  | 0    | 1    | 0 | 1-    |
| Atkins et al,<br>1999   | AQ (+)  | Triamcinolone or<br>hydrocortisone.<br>Approach or method<br>of guidance NS                          | 3 RCTs; N =<br>116 | Foot or heel pain, Foot<br>Function Index,<br>Maryland Foot Score,<br>AOFAS Ankle-Hind<br>Foot Rating, Ritchie<br>Tenderness Scale | <ul> <li>One non-blinded trial (Kriss 1990) found improvements in pain outcome for steroid inject alone, compared with steroid and insole intervention, whereas two other studies found no benefit of steroid injection compared to heel pads (Black 1991) or injection within saline (Blockey 1956).</li> <li>Given overall poor methodological quality of studies, it is not possible to produce robust evidence of effectiveness of any treatment for plantar</li> </ul>  | 0  | 1    | 0    | 0 | 1-    |
| Crawford et al,<br>2002 | HQ (++) | Triamcinolone or<br>hydrocortisone.<br>Approach or method<br>of guidance NS                          | 3 RCTs; N =<br>116 | Heel pain  | <ul> <li>fasciitis.</li> <li>Conflicting results, with one study found significant improvements in pain with steroid injection compared to insole (Kriss 1990) and another found no difference between steroid injection compared to heel pads (Black 1996).</li> <li>The effectiveness of steroid injection has not been demonstrated against placebo treatment, focusing on comparison to certain types of orthotic device.</li> <li>In all trials, improvement in heel pain was noted in both treated and processed grapuse.</li> </ul> | 0  | 1    | 0    | 0 | 1-    |
| Crawford et al,<br>2003 | HQ (++) | Triamcinolone, hydrocortisone, or prednisolone. Approach or method of guidance NS                    | 5 RCTs; N =<br>292 | Heel pain  | <ul> <li>non-treated groups.</li> <li>There is limited evidence for the effectiveness of local corticosteroid therapy.</li> <li>Steroid injections appear to be useful only in the short term and only to a small degree.</li> </ul>   | 0  | 1    | 1    | 0 | 1     |



#### Systematic Review: Injection of Steroid to the Plantar Fascia

| Lafuente et al,<br>2007 | LQ (-)  | Details not specified   | 4 RCTs; N = 273    | Heel pain   | <ul> <li>Steroid injections are useful in reducing heel pain, but only on the short-term and to a limited extent.</li> <li>Because multiple steroid injections are associated with weakness, plantar fat atrophy, and plantar fascia rupture, steroid injections should be reserved for cases that are refractory to other therapies.</li> </ul>                                   | 0   | 0 | 0 | 0 | 1- |
|-------------------------|---------|---|--------------------|---|--|-----|---|---|---|----|
| Li et al, 2015          | AQ (+)  | Prednisolone,<br>dexamethasone, or<br>methylprednisolone.<br>Approach or method<br>of guidance NS | 4 RCTs; N =<br>289 | Heel pain and plantar<br>fascial thickness after<br>one, two, and three<br>months | <ul> <li>Corticosteroids resulted in significant improvement in pain compared to placebo after one month (SMD=-0.32; 95%CI: -0.59 to -0.06; p=0.02); however there was no significant difference after two or three months.</li> <li>No significant difference was found in plantar fascial thickness for those treated with corticosteroid or placebo.</li> </ul>                 | . 1 | 1 | 0 | 0 | 1  |
| Tatli et al, 2009       | LQ (-)  | Prednisolone. Approach or method of guidance NS   | 1 RCTs; N =<br>106 | Heel pain   | • The single RCT examined (Crawford et al. 1999) demonstrated significant improvement in pain with steroid injection at one month, but not at 3 months following treatment.  | 0   | 0 | 0 | 0 | 1- |
| Tsikopoulos et al, 2016 | HQ (++) | Triamcinolone or<br>methylprednisolone.<br>Approach or method<br>of guidance NS                   | 3 RCTs; N =<br>140 | Heel pain   | • In the short-term (2-6 weeks after treatment), steroid injections were marginally more effective in relieving pain that autologous whole blood injection (SMD=0.55; 95%CI: 0.17 to 0.93; p=0.005). However, there was no significant difference at 24-26 weeks after treatment.  | 1   | 1 | 0 | 0 | 1  |
| Uden et al, 2011        | HQ (++) | Details not specified   | 2 RCTs; N =<br>189 | Heel pain   | <ul> <li>The two RCTs reviewed demonstrated short-term improvements in pain for corticosteroid injections versus treatments of electrocorporeal shock wave therapy or stretching exercises only (Porter &amp; Shadbolt 2005) or autologous blood injection (Lee &amp; Ahmad 2007).</li> <li>Corticosteroid injections were consistently considered painful by patients.</li> </ul> | 0   | 1 | 0 | 0 | 1- |





## Appendix 8: Data extraction table used in this review (RCTs)

| Au             | Year | 6            | Ste                | Do           | ; <b>†</b>   | Αp                                       | 6                                  |  | Pain                                     |   | F   | unctio     | nal ou | ıtcome  | es    | Conclusions   | Safety   | Imaging          |     |                                       |                   |   |                                       |  |
|----------------|------|--------------|--------------------|--------------|--------------|--|------------------------------------|--|--|---|-----|------------|--------|---------|-------|---|--|------------------|-----|---------------------------------------|-------------------|---|---------------------------------------|--|
| Author         | ar   | Country      | Steroid            | Dose (mg)    | +/- Local    | Approach                                 | Comparator                         | Outcome<br>measures  | Outcome<br>Assessme<br>Time poir         | Results   | ROM | Disability | RTW    | Quality | OTHER |   | and<br>Risk  |                  | P   | opula                                 | tion C            | harac                                       | teristi                               | CS                                     |
|                |      |              |                    |              | F            |  | or                                 | ures   | Outcome<br>Assessment<br>Time points     | g   |     | ility      |        | ty of   | ₽     |   |  |                  | Sam | Age                                   | Diag              | Diag  | Dura                                  | Prev                                   |
| Ahmed et al    | 2013 | Pakistan     | Methylprednisolone | 40mg         | +            | Medial side of area of tenderness in the | 4mg dexamethasone                  | Pain relief on first step, no tenderness on palpation at medial calcaneal tubercle (primary outcomes), persistant pain, and infection (secondary outcomes). VAS used for all pain measures | Baseline<br>and 4, 8,<br>and 12<br>weeks | Both steroid injections resulted in improvements in pain over a period of 12 weeks (no tests of significance conduced). In comparison to dexamethasone, methylprednisolone resulted in significantly greater improvements in heel pain at 4, 8, and 12 weeks after injection. |     |            |        | •       |       | Local methylprednisolone injection is superior to local dexamethasone injection, in providing short term pain relief to the patients with planter fasciitis.  | Adverse events observed in 13.3% of patients (pain after injection for 5 in intervention group | Palpation-guided | 60  | Mean (SD) = 48.3 (8.5)yrs             | Plantar fasciitis | Pain on palpation at the site of the medial | Pain in heel > 12 weeks               | Not satisfied with treatment over non- |
| Al-Bluwi et al | 2011 | Saudi Arabia | Not reported       | Not reported | Not reported | Not reported                             | EZStep orthotic device + NSAIDs OR | VAS for pain,<br>Short-Form<br>McGill Pain<br>Questionnaire<br>(SFMPQ)   | Baseline<br>and 24<br>weeks              | For both pain VAS and SFMPQ, steroid injection was significantly less effective than EZStep orthotic device but more effective than physiotherapy.  |     | •          |        |         |       | The present study was not intended to study the role of steroid injection in PF; however, while analyzing the data for comparing the study and control groups, we observed that the steroid and NSAID group fared significantly better than physiotherapy and NSAID group | Not reported   | Palpation-guided | 198 | Mean (SD) = 45.16(5.1)yrs for Ezstep, | Plantar fasciitis | Clinical symptoms, with alterior            | Mean (SD) = 12.33(7.4)wks for Ezstep, | Not reported                           |





|                 | 2013 | UK India | Methylprednisolone Met | 20mg 40mg | + | Insertion parallel to heel pad in line with the long axis of lnje | Placebo injection NSAID                     | VAS for pain, heel tenderness index, foot posture index, ultrasound of plantar fascia thickness    | Baseline and 6 and 12 weeks  Baseline and 1, 2, 4,  | Both US and palpation-guided steroid injection resulted in significant improvement in heel pain, heel tenderness index, and plantar fascia thickness at 6 and 12 weeks compared to placebo, with the exception of heel tenderness index at 6 weeks for US-guided steroid injection. There was no difference between US and palpation-guided approaches  Pain was significantly lower |   | •                                     | • | • |   | Patients in both the ultrasound guided and unguided injection groups showed a statistically significant reduction in VAS pain scores, heel tenderness, and plantar fascia thickness when compared with the placebo group. There was no difference in outcome for US vs palpation-guided injection  Local injection of steroid is more         | No adverse events reported 58/6               | US or palpation-guided | 65 120 | Mean (SD) = 49 (11.3)yrs Mean  | Plantar fasciitis Unil       | History of heel pain + point tenderness over the medial Not | Median (range) = 6 (2.5-60) months < 3        | Failed to respond to at least 8 weeks of conservative No particles and the conservative No particles are the conservative no particles and the conservative no particles are the |
|-----------------|------|----------|------------------------|-----------|---|---|---|--|---|--|---|---------------------------------------|---|---|---|---|---|------------------------|--------|--------------------------------|------------------------------|---|---|--|
| Biswas et al    | .1   | ä        | Methylprednisolone     | ng        |   | Injected into the tender most                                     | AD .  | heel pain  | and 8<br>weeks                                      | for the steroid injection group at all timepoints. The recurrence of heel pain was significantly lower in the steroid group (6/60 patients vs 33/60 patients for NSAID).   |   |                                       |   |   |   | effective in the<br>treatment of<br>plantar fasciitis than<br>oral NSAIDs   | 58/60 patients in the NSAID group experienced | Palpation-guided       |        | Mean (SD) = 38.4 (11.6)yrs for | Unilateral plantar fasciitis | Not reported  | months pain                                   | No prior treatment   |
| Canyilmaz et al | 2015 | Turkey   | Methylprednisolone     | 40mg      | + | Anteromedial insertion  | Radiation therapy                           | VAS for pain,<br>modified von<br>Pannewitz<br>pain score,<br>and 5-level<br>function score         | Baseline<br>and every<br>6 weeks<br>for 6<br>months | Pain VAS, function score, and pain score were significantly improved in the radiotherapy group compared to steroid injection at 3 and 6 months   | 1 | ,                                     |   |   |   | Radiation therapy is<br>more effective at<br>relieving pain than<br>palpation-guided<br>steroid injection for<br>plantar fasciitis  | One case of injection site infection was      | Palpation-guided       | 128    | Mean (range) = 54.7            | Painful heel spur            | Clinical diagnosis of                                       | > 6 months                                    | Not reported   |
| Celik et al     | 2016 | Turkey   | Methylprednisolone     | 40mg      | + | Medial  | Joint mobilisation and stretching exercises | VAS for pain<br>(during daily<br>living<br>activities) and<br>Food and<br>Ankle Ability<br>Measure | Baseline<br>and 3, 6,<br>12, and 52<br>weeks        | Pain and functional outcomes improved at 3, 6, and 12 weeks follow-up for both groups, with significantly better results for steroid injection. There was no significant difference between groups at 12 months for either outcome   | • | Foot and Ankle Ability Measure (FAAM) | • | • | • | While both groups achieved significant improvements at the 3, 6, and 12 week follow-ups, the steroid injection group demonstrated better outcomes at all 3 time points. Improvements were sustained for the joint mobilisation and stretching group for a period of time ranging from 12 weeks to 1 year, but not for the steroid injections. | No adverse events reported                    | Palpation-guided       | 43     | Meas (SD) = 45.5 (8.5)yrs      | Plantar fasciitis            | Tenderness over the medial tubercle of the                  | Mean (SD) = 13.1 (2.6)mo for steroid and 11.2 | Not reported   |





| Circle Cred | 2013 | Taiwan | Betamethasone | 7mg | + | Posterior heel | device-guided ultrasound vs palpation guidance injections | VAS for pain,<br>tenderness<br>threshold,<br>heel pad<br>thickness,<br>plantar fascia<br>thickness, and<br>SF-36<br>(physical<br>subscale) | Baseline<br>and 3<br>weeks and<br>3 months | Both US and palpation-guided steroid injection resulted in significant improvements in heel pain, tenderness threshold, and thickness of the plantar fascia. The device-assisted US-guided group demonstrated significantly improved tenderness threshold and pain score compared to the palpation group. Physical health status was significantly higher in the device-assisted group, although this was |  |  | Device-assisted ultrasound-guided injection for treating plantar fasciitis results in better therapuetic outcomes than palpation-guided injection | Not reported | US vs palpation-guided | 33 | Mean (SD) = 54.25 (11.7)yrs for palpation-guided and 55.69 (9.38)yrs for de | Unilateral plantar fasciitis | Tenderness to the pressure at the origin of the plantar fascia on the medial | > 8 weeks | Failure to respond to at least 4 weeks of conservative treatment |
|-------------|------|--------|---------------|-----|---|----------------|---|--|--|---|--|--|---|--------------|------------------------|----|---|------------------------------|--|-----------|--|
|             |      |        |               |     |   |                |   |  |  | significantly higher in the device-   |  |  |   |              |                        |    |   |                              |  |           | nt   |





| Diaz-Llopis et al | 2011 | Spain | Betamethasone      | 12mg | + | Area of the calcaneal tuberosity                        | Botulinum toxin type A                          | Foot Health<br>Status<br>Questionnaire   | Baseline and 1 and 6 months      | One month after injection there was a clear clinical improvement in both treatment groups but it was greater in the botulinum toxin group, with a significant difference for the pain item (P=0.069), though not in other items. At six months, patients treated with botulinum toxin type A had continued to improve in all items, whereas the corticosteroid group lost part of the improvement achieved at one month (improvement with botulinum toxin vs. corticosteroid: pain 19.10/–6.84 (P=0.001), function 16.00/–8.80 (P<0.001), footwear 13.48/–7.95 (P=0.004), self-perceived foot health 25.44/–5.41 (P<0.001) | Foot Health Status Questionnaire |   |                                     | Botulinum toxin type A should be considered for the treatment of chronic plantar fasciitis in view of the improvement found at one month, and particularly at six months, when this treatment clearly has better results than corticosteroid injections. Further studies with larger samples are necessary to confirm these results    | No adverse events reported | Palpation-guided | 56 | Mean (SD) = $51.50 (14.79)$ yrs for botulinum group and $56.36 (14.71)$ yrs for the steroid group | Chronic plantar fasciitis | Presence of heel pain during the first steps after a period of rest or exacerbated by walking/standing over | > 6 months | Failure of conservative interventions (NSAIDs, heel pads, insoles, night splints) and stretching exercises |
|-------------------|------|-------|--------------------|------|---|---|---|--|----------------------------------|--|----------------------------------|---|-------------------------------------|--|----------------------------|------------------|----|---|---------------------------|---|------------|--|
| Eslamian et al    | 2016 | Iran  | Methylprednisolone | 40mg | + | Most tender point (medial plantar or inferior calcaneal | Radial extracorporeal shock wave therapy (ESWT) | VAS for pain (morning and daytime), Functional Foot Index, patient satisfaction with treatment | Baseline<br>and 2 and<br>8 weeks | Pain and FFI score improved significantly for both groups, with no significant between group differences. There was no significant difference in satisfaction between groups   | Foot Function Index              | • | Patient satisfaction with treatment | Both interventions caused improvement in pain and functional ability 2 months after treatment. Although intergroup differences were not significant, foot function was improved more with ESWT and patients were more satisfied with ESWT, thus shockwave therapy seems a safe alternative for management of chronic plantar fasciitis | No adverse events reported | Palpation-guided | 40 | Mean (SD) = 41.45 (8.05)yrs for ESWT group and 42.85  | Chronic plantar fasciitis | Tenderness to pressure at origin of the PF on the medial  | > 2 months | Failure of conservative therapies (PT, NSAIDs, stretching  |





| Guner et al     | 2013 | Turkey | Methylprednisolo   | 40mg | + | Medial approach   | Tenoxicam                                     | VAS for pain,<br>and Roles and<br>Maudsley<br>Score (patient<br>satisfaction)  | Baseline<br>and 6 and<br>12 months  | There was a significant improvement in pain for both groups, with no between group differences.  | Roles and   | • | • | Both tenoxicam and<br>steroid injection are<br>similarly effective at<br>treating patients<br>with PF  | No adverse events reported | Palpation-guided | 61 | Mean (SD) = 41.4               | Plantar fasciitis         | Tenderness at            | > 3 months                  | Failture of   |
|-----------------|------|--------|--------------------|------|---|---|---|--|---|--|---|---|---|--|----------------------------|------------------|----|--------------------------------|---------------------------|--------------------------|-----------------------------|---|
| Hanselman et al | 2015 | USA    | Methylprednisolone | 40mg | + | Approach toward the medial calcaneal tuberosity down to the level of the periosteum | Cryopreserved human amniotic membrane (c-hAM) | Foot Health Status Questionnaire (FHSQ), VAS for pain, and patient- reported % improvement                             | Baseline<br>and 6 and<br>12 weeks<br>(18 weeks<br>in 2-<br>injection<br>cohort) | In the 1-injection group, shoe fit at 6 weeks (P = .0244) and general health at 6 weeks (P = .0132) were statistically greater in the steroid group. In the 2-injection group, foot pain score at 18 weeks (P = .0113) was statistically greater in the c-hAM group, indicating an improvement in foot pain. All other variables resulted in no significant difference. There were no significant differences between groups for pain scores. Patient-reported improvement in symptoms at 12 weeks was significantly great in the 1-injection steroid group. | FHSQ  |   |   | Cryopreserved human amniotic membrane injection may be safe and comparable to corticosteroid injection for treatment of PF. This is a pilot study and requires further investigation   | No adverse events reported | Palpation-guided | 24 | Mean (range) = 51.0 (32-65)yrs | Plantar fasciitis         | Clinical diagnosis of PF | Between 3 months and 1 year | Not reported  |
| Jain et al      | 2015 | UK     | Triamcinolone      | 40mg | + | Point of maximal tenderness using the peppering technique                           | Platelet rich plasma (PRP) injection          | Roles-<br>Maudsley<br>Score, VAS for<br>pain, and the<br>American<br>Orthopaedic<br>Foot and<br>Ankle Society<br>Score | Baseline<br>and 3, 6,<br>and 12<br>months                                       | At 3 months, both steroid and PRP groups demonstrated significant improvements across all outcomes, with no significant between-group differences. At 6 months there was no significant difference between groups for any outcome. At 12 months, all outcomes were significantly better for PRP than for steroid.  | Roles and Maudsley Score and the American Orthopaedic | • | • | PRP is as effective as steroid injection at achieving symptom relief at 3 and 6 months after injection, for the treatment of plantar fasciitis, but unlike steroid, its effect does not wear off with time. At 12 months, PRP is significantly more effective than steroid, making it better and more durable than cortisone injection | No adverse events reported | Palpation-guided | 60 | Mean (range) = 55.6 (31-79)yrs | Chronic plantar fasciitis | Not reported             | > 12 months                 | Not responded to cushioned insoles, stretching exercises, |





| Li et al  | Lee & Ahmad   | Kiter et al   |
|---|---|---|
| 2014  | 2007  | 2006  |
| China   | Malaysia  | Turkey  |
| Triamcinolone   | Triamcinolone   | Methylprednisolone  |
| 20mg  | 20mg  | 40mg  |
| +   | +   | +   |
| Injected into the tender most point   | Medial side of foot near the plantar surface  | Plantar aspect of the   |
| Miniscalpel needle release  | Intralesional autologous blood  | Anaesthetic using the   |
| VAS for pain<br>(morning,<br>activity,<br>overall<br>ratings)   | VAS for pain and tenderness threshold (using pressure algometer)  | VAS for pain,<br>rearfoot score<br>of the<br>American<br>Orthopaedic<br>Foot and<br>Ankle Society   |
| Baseline,<br>and 1, 6,<br>and 12<br>months  | Baseline, 6<br>weeks, 3<br>months,<br>and 6<br>months   | Baseline<br>and 6<br>months   |
| groups over time.  All measures of pain significantly improved at 1, 6, and 12 months compared to baseline after microscalpel-needle release treatment, whereas steroid injection resulted in improvements at 1 month but not at 6 or 12 months | There were significant improvements in pain and tenderness threshold for both treatment groups, although there was no significant between-group differences at 6 months. Steroid injection had significantly better tenderness threshold compared with autologous blood at 6 weeks, 4 months, and 6 months. Repeated-measures F test for pain and tenderness threshold showed no significant difference between | At 6 months, all<br>treatments resulted<br>in significant<br>improvements in<br>pain and AOFAS<br>score, with no<br>significant<br>between-group<br>differences |
| •   |   | •   |
|   |   | AOFAS score   |
|   |   | -   |
|   |   | -   |
| D   |   | •   |
| Miniscalpel-Needle<br>treatment is safe<br>and more effective<br>than steroid<br>injection in treating<br>PF  | Intralesional autologous blood injection is efficacious in lowering pain and tenderness in chronic plantar fasciitis, but corticosteroid is more superior in terms of speed and probably extent of improvement  | Autologous blood or anaesthetic injected using the peppering technique are comparable in effectiveness to steroid injection                                     |
| For mini-scalpel needle - 6 reports of minor side-effects residing  | No reports of fat pad atrophy, infections, or rupture of the PF. All patients found the injections painful  | Not reported  |
| Palpation-guided  | Palpation-guided  | Palpation-guided  |
| 61  | 64  | 45  |
| Mean (SD) = 54.74 (10.16)yrs fpr  | Mean (SD) = $48.3 (10.5)$ yrs for autologous blood and $49.2 (11.1)$ yrs for steroid  | Mean (range) = 50.7   |
| Plantar fasciitis   | Chronic plantar fasciitis   | Plantar fasciitis   |
| Heel pain localised to the medial   | Complaint of plantar heel pain, worse on rising in morning and/or after   | Not reported  |
| > 6 months  | > 6 weeks   | > 6 monts   |
| Failed to respond to at least 6   | Not reported  | Failure of conservative   |





| 2012<br>McMillan et al  | 2015<br>Mardani-Kivi   | 2016<br>Mahindra et al   |
|---|--|--|
| Dexamethasone Australia   | Methylprednisolone<br>Iran   | Methylprednisolone<br>India  |
| 4mg   | +<br>40mg  | Not reported 40mg  |
| Medial oblique approach, guided by US into  | Injected into point of maximum   | Injected into the tender most point of the plantar fascia,   |
| Placebo (saline) injection  | Extracorporeal shock wave therapy  | Platelet rich plasma (PRP) injection and placebo injection   |
| Pain rating<br>(foot pain<br>domain of<br>foot health<br>status<br>questionnaire)<br>and PF<br>thickness  | VAS for pain, pain recurrence  | VAS for pain<br>and American<br>Orthopaedic<br>Foot and<br>Ankle Society<br>(AOFAS) Ankle<br>and Hindfoot<br>score   |
| Baseline<br>and 4, 8,<br>and 12<br>weeks  | Baseline<br>and 3, 6,<br>and 12<br>weeks   | Baseline, 3<br>weeks, and<br>3 months  |
| There was significantly greater improvement in pain for steroid injection compared to placebo at 4 weeks, but not at 8 or 12 weeks. PF thickness was significantly better for the steroid injection group at 4, 8, and 12 weeks                         | Pain intensity significantly improved in both groups compared to baseline at all time points, with significantly greater improvement in favour of steroid injection. Treatment failure in 14.7% of cases for steroid injection and 55.9% of cases for ESWT | There were significant improvements in pain and AOFAS score at 3 weeks and 3 months for both treatment groups, but not for placebo. There were no significant differences between platelet rich plasma injection and steroid injection, with the exception of significantly better AOFAS score in the plasma-rich plasma group at 3 months |
| •   |  | •  |
| •   |  | AOFAS score  |
|   |  |  |
| •   |  | •  |
|   |  |  |
| A single ultrasound guided dexamethasone injection is a safe and effective short term treatment for PF. It provides greater pain relief than placebo at four weeks and reduces abnormal swelling of the PF for up to three months; however, significant | Both ESWT and steroid injection can be used as initial treatment options for treating patients with acute plantar fasciitis; however, steroid injection is more effective  | Local injection of platelet-rich plasma or corticosteroid is an effective treatment option for chronic PF. Platelet-rich plasma injection is as effective if not more effective than corticosteroid injection in treating chronic PF   |
| No adverse events reported  | Not reported   | Not reported   |
| US-guided   | Palpation-guided   | Palpation-guided   |
| 82  | 84   | 75   |
| Mean (SD) = 51.7 (11.9)yrs for steroid group  | Mean (SD) = 43.91 (7.96)yrs for ESWT   | Mean (SD) = $30.72$ (7.42)yrs for autologous blood, $33.92$  |
| Plantar fasciitis   | Acute plantar fasciitis  | Chronic plantar fasciitis  |
| Pain on palpation of the medial calcaneal   | Morning heel pain, local tenderness at   | Heel pain localised to the medial tubercle of the calcaneum  |
| > 8 weeks   | < 6 weeks  | > 3 months   |
| Not currently receiving treatment for PF  | Not previously treated   | Failed to respond to conservative therapy (PT, NSAIDs,   |





| Monto            | 2014 | USA   | Methylprednisolone | 40mg         | +            | Periosteum of the                                 | Platelet-rich plasma           | American Orthopaedic Foot and Ankle Society (AOFAS) Ankle and Hindfoot score | Baseline<br>and 3, 6,<br>12, and 24<br>months   | platelet-rich plasma<br>injection resulted in<br>significantly greater<br>improvement in<br>AOFAS score<br>compared with<br>steroid injection at<br>3, 6, 12, and 24-<br>months   |   | AOFAS score | - | 1 | 1 | Platelet-rich plasma<br>injection was more<br>effective and<br>durable than<br>steroid injection for<br>the treatment of<br>chronic recalcitrant<br>cases of PF   | Not reported | US-guided        | 40  | Mean (range) = 59 (24-                       | Chronic plantar fasciitis  | Radiographic and MRI                         | > 4 months   | Non responsive to > 4 |
|------------------|------|-------|--------------------|--------------|--------------|---|--------------------------------|--|---|---|---|-------------|---|---|---|---|--------------|------------------|-----|--|----------------------------|--|--------------|-----------------------|
| Motififard et al | 2008 | Iran  | Prednisolone       | 80mg         | Not reported | Injected into                                     | Heel pad                       | VAS for pain   | Baseline<br>and 6<br>months   | Steroid injection +<br>casting was<br>significantly more<br>effective than heel<br>pad alone.   | , | ,           | • | • | • | Corticosteroid injection together with casting was more effective at treating heel pain than use of heel pads   | Not reported | Not reported     | 90  | Not reported                                 | Heel pain                  | Not reported                                 | Not reported | No previous           |
| Mulherin & Price | 2009 | UK    | Methylprednisolone | 80mg         | +            | Injected directly to the PF, through the heel pad | Tibial nerve block             | VAS for pain<br>and Heel<br>Tenderness<br>Index                              | Baseline<br>and 1, 6,<br>and 26<br>weeks<br>(baseline<br>and 6<br>weeks for<br>Heel<br>Tenderness<br>Index) | All groups demonstrated significant improvement in pain between baseline and weeks 1, 6, and 26, with a significant between-group difference at 6 weeks for steroid injection alone vs anaesthetic block or steroid injection + anaesthetic block. Heal Tenderness Index was significantly better for anaesthetic block alone at 6 weeks compared to the other groups |   |             |   |   |   | Although there is a natural course of improvement with Plantar Heel Pain Syndrome, a tibial nerve block reduces the discomfort of the procedure, that a steroid injection to the heel may accelerate improvement and that clinicians should consider a combination of both strategies | Not reported | Palpation-guided | 45  | Median (10–90 percentile) = 55 (33–68) years | Plantar Heel Pain Syndrome | Median (10-90 percentile) = 10 (4–36) months | Not reported | Not reported          |
| Narula et al     | 2014 | India | Methylprednisolone | 40mg         | +            | Not reported                                      | Conservative treatment         | VAS for pain   | Baseline, 4,<br>and 8<br>weeks  | No significant<br>difference between<br>groups at 4 or 8<br>weeks   | 1 | 1           | - | - | • | As both treatment modalities are comparative in treatment outcome, it is better to go for conservative approach because this can avoid the complications of steroid therapy   | Not reported | Palpation-guided | 276 | Most frequent age group                      | Plantar fasciitis          | Pain on waking or after                      | Not reported | Not reported          |
| Omar et al       | 2012 | Egypt | Not reported       | Not reported | Not reported | Not reported                                      | Platelet-rich plasma injection | VAS for pain<br>and Foot<br>Health Status<br>Questionnaire<br>(FHSQ)         | Baseline<br>and 6<br>weeks  | Both treatments resulted in significant improvements in pain and FHSQ score at 6 weeks, with significantly greater improvement in the PRP group compared with the steroid group   | , | FHSQ        | • | 1 | • | PRP was more<br>effective than<br>steroid injection in<br>relieving the short-<br>term symptoms of<br>PF  | Not reported | Not reported     | 30  | Mean (SD) = 44.5 (15.5)yrs for               | Plantar fasciitis          | Inferior heel pain that is worse             | Not reported | Not reported          |





| Tiwari & Bhargava  | Saba & El-Sherif  | Ryan et al   |
|--|---|--|
| 2013   | 2015  | 2014   |
| India  | Egypt   | Canada   |
| Methylprednisolone   | Triamcinolone   | Dexamethasone  |
| 40mg   | 20mg  | Not reported   |
| +  | +   | +  |
| Medial aspect of the heel at   | Medial approach through the maximally tender  | Anteromedial to the focal point of pain in the inferior  |
| Platelet-rich plasma injection   | US vs palpation-guided  | Physiotherapy-based exercise program   |
| VAS for pain   | VAS for pain,<br>Plantar<br>Fasciitis<br>Pain/Disability<br>Scale, PF<br>thickness and<br>echogenicity<br>(US-assessed)   | VAS for pain<br>(at work and<br>with activities<br>of daily living),<br>Foot and<br>Ankle<br>Disability<br>Index, and PF<br>thickness (US-<br>assessed)  |
| Baseline, 1,<br>3, and 6<br>months   | Baseline, 2<br>and 4<br>weeks   | Baseline<br>and 6 and<br>12 weeks  |
| At 1 month, both treatment groups demonstrated a significant improvement in pain, sustained at 3 and 6 months. PRP resulted in significantly greater pain reduction than steroid injection at 1, 3, and 6 months | Significant improvements for all outcomes in both groups, with no between group differences at either 2 or 4 weeks. At 4 weeks after injection, the hypoechogenicity disappeared in all patients of both groups   | Significant improvements observed for pain and FADI at 6 and 12 weeks compared with baseline, with no between group differences. No significant changes to PF thickness at any timepoint, although the number of cases with focal anechoic areas and the size of these areas improvemed significantly in both groups at 12 weeks |
|  |   |  |
|  | Plantar Fasciitis Pain/Disability Scale   | Foot and Ankle Disability Index  |
|  |   |  |
|  |   | •  |
|  |   |  |
| PRP injection is<br>more effective than<br>steroid injection at<br>relieving pain from<br>PF   | Ultrasound-guided and palpation-guided local corticosteroid injections were effective and successful in treatment of PF. Both techniques improved PF clinically and ultrasonographically without statistically significant superior results for the ultrasound-guided injection | Workers standing for prolonged periods experienced the same short-term therapeutic effectiveness with a physiotherapy led exercise program compared with an injection of corticosteroid with stretching  |
| Not adverse events reported  | Not adverse events reported   | Not reported   |
| Radiographically marked  | US vs palpation-guided  | Palpation-guided   |
| 60   | 21  | 65   |
| Not reported   | Mean (SD) = 45.20 (11.75)yrs for US group and   | Mean (SD) = $52.4 (7.5)$ yrs for PT and $46.2 (8.5)$ yrs for   |
| Plantar fasciitis  | Chronic idiopathic plantar fasciitis  | Chronic plantar fasciitis  |
| tenderness centered on the   | Presence of post-static dyskinesia, presence of   | Inferior heel pain with pain through direct palpation  |
| Not reported   | >3 months   | >12 months   |
| Mixture of previous therapies  | Non-responsive to conservative treatment  | Not reported   |





| Yucel et al   | Yesiltas et al  | Tsai et al  |
|---|---|---|
| 2010  | 2015  | 2006  |
| Turkey  | Turkey  | Taiwan  |
| Betamethasone   | Triamcinolone   | Betamethasone   |
| 2.2mg   | Not reported  | 7mg   |
| +   | Anaesthetic spray   | +   |
| Medial side of heel   | Not reported  | Posterior heel parallel to the long axis of the transducer (US) or  |
| Extracorporeal shock  | Autologous venous blood injection   | US vs palpation-guided  |
| VAS for pain<br>and heel<br>tenderness<br>index   | VAS for pain,<br>heel pad<br>thickness, and<br>diameter of<br>inflammation<br>site  | VAS for pain,<br>tenderness<br>threshold, PF<br>thickness, PF<br>echogenicity,<br>and<br>recurrence of<br>heel pain   |
| Baseline<br>and 3<br>months   | Baseline, 6<br>weeks, 3<br>months,<br>and 6<br>months   | Baseline, 2<br>weeks, 2<br>months,<br>and 1 year  |
| Both treatments resulted in significant improvements in pain and heel tenderness index scores, with no significant between group difference | Both treatment groups resulted in significant improvements in pain at 6 weeks, 3 months, and 6 months, with no significant between group differences. Compared with autologous blood injection, steroid injection was significantly more effective at reducing heel pad thickness and diameter of the inflammation site | Pain, tenderness threshold, PF thickness, and PF echogenicity improved significantly in both groups. Between group analyses favoured sonographic guideance for improving tenderness threshold at 2 weeks, 2 months, and 1 year, for improving pain at 1 year, and reducing PF thickness at 1 year. Recurrence of heel pain was significantly greater in the palpation- guided group |
| 1   |   |   |
| 1   |   |   |
| -   |   | •   |
| 1   |   | •   |
| 1   |   |   |
| Corticosteroid<br>injection and ESWT<br>are comparable in<br>effectiveness in<br>treating the<br>symptoms of<br>chronic PF                  | Intralesional steroid injection and autologous venous blood injection have comparable effectiveness in the treatment of pain with PF, although steroid injection was more effective at improving heel pad thickness and the diameter of the site of inflammation  | Steroid injection can be an effective way to treat PF, and injection under sonographic guidance is associated with lower recurrence of heel pain  |
| All persons receiving steroid injection had   | Not reported  | Not reported  |
| Palpation-guided  | US-guided   | US vs palpation-guided  |
| 60  | 60  | 25  |
| Mean (SD) = 43.9  | Mean (SD) = $42.71$ (8.07)yrs for autologous blood  | Mean (SD) = $49.8$ (10.8)yrs for palpation group and 53.0 (11.4)yrs for   |
| Chronic plantar fasciitis   | Plantar fasciitis   | Plantar fasciitis   |
| Post-static dyskinesia  | Not reported  | Tenderness to pressure at the origin of the PF on the medial tubercle   |
| > 6 months  | Mean (SD) = $30.21$ ( $30.82$ ) months for autologous   | >2 months   |
| Failed to respond to > 6  | Not reported  | Non-responsive to conservative treatments (NSAIDs, US diathermy,  |





| 2013<br>Yucel et al   | 2009<br>Yucel et al   |
|---|---|
| Turkey  | Turkey  |
| Betamethasone   | Betamethasone   |
| 4.5mg   | +<br>3.2mg  |
| Medial approach   | Medial approach   |
| Full-length silicone insole   | Palpation, US, or scintigraphy-guided   |
| VAS for pain,<br>Heel<br>Tenderness<br>Index, Foot<br>and Ankle<br>Outcome<br>Score (FAOS),<br>PF thickness   | VAS for pain<br>intensity, heel<br>pad thickness,<br>and PF<br>thickness  |
| Baseline<br>and 1<br>month  | Baseline<br>and 25.3<br>months  |
| at follow-up  Significant improvements were observed for both groups in VAS, Heel Tenderness Index, FAOS, PF thickness. Pain scores, FAOS for pain, FAOS for activities of daily living, FAOS for sport and recreation function, and PF thickness | US-guidance resulted in significant improvements in pain, heel pad thickness, and PF thickness, palpation-guidance resulted in significant improvements in pain and PF thickness, and scintigraphic- guidance resulted in improvement in pain only. There were no between group differences |
|   | •   |
| FAOS  | •   |
|   | •   |
| FAOS  | •   |
|   | •   |
| Both ultrasound- guided corticosteroid injection and wearing a full- length silicone insole were effective in the conservative treatment of PF, although we recommend the use of silicone insoles as a first line of                              | US-, palpation-, and scintigraphy-guidance were all effective in the treatment of plantar fasciitis, and there was no statistically significant difference between these techniques in terms of plantar fascia thickness, fat pad thickness, and pain rating                                |
| No adverse events reported  | Not reported  |
| US-guided   | Palpation, US, or scintigraphy-guided   |
| 44  | 27  |
| Mean (SD) = 45.6 (9.3)yrs for steroid and   | Mean (SD) = 45.8 (12.0)yrs  |
| Chronic plantar fasciitis   | Plantar fasciitis   |
| Tenderness localized to the medial tubercle   | Tenderness localised to the medial tubercle of the  |
| > 3 months  | Not reported  |
| Not reported  | Failed to respond to conservative treatment with  |

**END OF DOCUMENT** 

